[{"trial_id":259,"discovery_date":"2021-09-17T15:00:09","title":"A Long-term Extension of Study GNC-401","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Drug: Temelimab 18 mg&#x2F;kg;   Drug: Temelimab 36mg&#x2F;kg;   Drug: Temelimab 54 mg&#x2F;kg&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    GeNeuro Innovation SAS&lt;br&#x2F;&gt;&lt;b&gt;Recruiting&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT05049161?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","published_date":"2021-09-17T16:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":258,"discovery_date":"2021-09-16T16:50:09","title":"The Effect of Cigarette Smoke on Sleep Quality and Physical Activity in People With Multiple Sclerosis","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Behavioral: Sleep quality and physical activity;   Genetic: Nicotine dependence;   Diagnostic Test: Nicotine and cotinine serum levels;   Behavioral: Smoking&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    University of Jordan&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT05046535?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","published_date":"2021-09-16T16:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":257,"discovery_date":"2021-09-06T00:04:28","title":"A Multicenter Open-label Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With Somatostatin Receptor Positive Gastroenteropancreatic Neuroendocrine (GEP-NET) Tumors, Pheochromocytoma and Paragangliomas (PPGL)","summary":"","link":"https://www.novartis.com/clinicaltrials/study/nct04711135","published_date":"","source":"Novartis","relevant":null,"table_constraints":null,"sent":1},{"trial_id":256,"discovery_date":"2021-09-06T00:04:27","title":"A Randomized, Four-arm, Placebo-controlled, Participant, Investigator and Sponsor-blinded Study Investigating the Safety, Tolerability and Efficacy of Intra-articular Canakinumab Followed by Intra-articular LNA043 in Patients With Knee Osteoarthritis","summary":"","link":"https://www.novartis.com/clinicaltrials/study/nct04814368","published_date":"","source":"Novartis","relevant":null,"table_constraints":null,"sent":1},{"trial_id":255,"discovery_date":"2021-09-05T16:31:06","title":"Impact of the Modifications of Environmental Exposures and Health Care Access During COVID-19 Lockdown on Multiple Sclerosis","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Other: questionnaire&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Assistance Publique - Hôpitaux de Paris&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT05033782?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","published_date":"2021-09-03T16:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":254,"discovery_date":"2021-09-02T23:31:19","title":"Open Label, Multi-center Roll-over Study to Assess Long Term Safety in Patients Who Have Completed a Global Novartis or GSK Sponsored Dabrafenib and&#x2F;or Trametinib Study","summary":"","link":"https://www.novartis.com/clinicaltrials/study/nct03340506","published_date":"","source":"Novartis","relevant":null,"table_constraints":null,"sent":1},{"trial_id":253,"discovery_date":"2021-09-02T23:31:19","title":"A Randomized, Multi-center, Subject and Investigator-blinded, Placebo-controlled, Parallel-group Study to Assess the Efficacy Safety and Tolerability of LYS006 in Patients With Mild to Moderate Ulcerative Colitis","summary":"","link":"https://www.novartis.com/clinicaltrials/study/nct04074590","published_date":"","source":"Novartis","relevant":null,"table_constraints":null,"sent":1},{"trial_id":252,"discovery_date":"2021-09-02T23:31:19","title":"A Phase II Randomized Study of the Combination of Ribociclib Plus Goserelin Acetate With Hormonal Therapy Versus Physician Choice Chemotherapy in Premenopausal or Perimenopausal Patients With Hormone Receptor-positive&#x2F; HER2-negative Inoperable Locall ...","summary":"","link":"https://www.novartis.com/clinicaltrials/study/nct03839823","published_date":"","source":"Novartis","relevant":null,"table_constraints":null,"sent":1},{"trial_id":251,"discovery_date":"2021-09-02T23:31:19","title":"Special Drug Use-results Surveillance of Tabrecta Tablets (MET Exon 14 Skipping Mutation-positive Unresectable Advanced&#x2F;Recurrent Non-small Cell Lung Cancer)","summary":"","link":"https://www.novartis.com/clinicaltrials/study/nct04575025","published_date":"","source":"Novartis","relevant":null,"table_constraints":null,"sent":1},{"trial_id":250,"discovery_date":"2021-09-02T23:31:19","title":"The Multi-National Gilenya Pregnancy Exposure Registry in Multiple Sclerosis","summary":"","link":"https://www.novartis.com/clinicaltrials/study/nct01285479","published_date":"","source":"Novartis","relevant":null,"table_constraints":null,"sent":1},{"trial_id":249,"discovery_date":"2021-09-01T16:27:57","title":"Development and Application of Tele-Neuro Rehabilitation System","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Stroke;   Multiple Sclerosis;   Parkinson Disease&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Other: Telerehabilitaton;   Other: Home Exercise&lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    Istanbul University-Cerrahpasa;   The Scientific and Technological Research Council of Turkey&lt;br&#x2F;&gt;&lt;b&gt;Recruiting&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT05031403?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","published_date":"2021-09-01T16:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":248,"discovery_date":"2021-09-01T16:27:57","title":"Assessment of Quality of Life and Psychological Problems in Patients With Multiple Sclerosis","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis Acute and Progressive&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Combination Product: investigations like MRI..&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Assiut University&lt;br&#x2F;&gt;&lt;b&gt;Recruiting&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT05029830?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","published_date":"2021-09-01T16:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":247,"discovery_date":"2021-09-01T02:31:19","title":"AcTION: A Phase I Study of 225Ac-PSMA-617 in Men With PSMA-positive Prostate Cancer and Extensive Skeletal Metastases","summary":"","link":"https://www.novartis.com/clinicaltrials/study/nct04597411","published_date":"","source":"Novartis","relevant":null,"table_constraints":null,"sent":1},{"trial_id":246,"discovery_date":"2021-09-01T02:31:19","title":"A 52-weeks Observational Study to Evaluate the Safety of Brolucizumab (6mg) in Patients With Neovascular Age-related Macular Degeneration (nAMD)","summary":"","link":"https://www.novartis.com/clinicaltrials/study/nct04632056","published_date":"","source":"Novartis","relevant":null,"table_constraints":null,"sent":1},{"trial_id":245,"discovery_date":"2021-09-01T02:31:19","title":"A Multicenter, Open-label Post Authorization Safety Study to Evaluate the Effect of LysaKare® Infusion on Serum Potassium Levels in GEP-NET Patients Eligible for Lutathera® Treatment","summary":"","link":"https://www.novartis.com/clinicaltrials/study/nct04524442","published_date":"","source":"Novartis","relevant":null,"table_constraints":null,"sent":1},{"trial_id":244,"discovery_date":"2021-09-01T02:31:19","title":"A Phase I&#x2F;IIa Open-label, Multi-center Study to Evaluate the Safety, Tolerability, Whole-body Distribution, Radiation Dosimetry and Anti-tumor Activity of [177Lu]-NeoB Administered in Patients With Advanced Solid Tumors Known to Overexpress Gastrin-r ...","summary":"","link":"https://www.novartis.com/clinicaltrials/study/nct03872778","published_date":"","source":"Novartis","relevant":null,"table_constraints":null,"sent":1},{"trial_id":243,"discovery_date":"2021-08-31T15:55:08","title":"Phase 1b Multiple Ascending Dose Study of Foralumab in Primary and Secondary Progressive MS","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Primary Progressive Multiple Sclerosis;   Secondary Progressive Multiple Sclerosis;   Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Drug: Intranasal Foralumab Solution;   Drug: Placebo&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Tiziana Life Sciences, PLC&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT05029609?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","published_date":"2021-08-31T16:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":242,"discovery_date":"2021-08-31T15:55:08","title":"Hematopoietic Stem Cell Transplantation for Treatment of Multiple Sclerosis in Sweden","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Multiple Sclerosis;   Multiple Sclerosis, Relapsing-Remitting&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Procedure: Autologous hematopoietic stem cell transplantation&lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    Uppsala University;   Karolinska University Hospital;   Sahlgrenska University Hospital, Sweden;   Uppsala University Hospital;   Skane University Hospital;   University Hospital, Linkoeping;   University Hospital, Umeå;   Region Örebro County&lt;br&#x2F;&gt;&lt;b&gt;Recruiting&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT05029206?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","published_date":"2021-08-31T16:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":241,"discovery_date":"2021-08-31T15:55:08","title":"The Effects of Trunk Stabilization and Aerobic Trainings in Multiple Sclerosis","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Physical Therapy&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Other: Combined exercise training;   Other: Aerobic training&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Ankara Yildirim Beyazıt University&lt;br&#x2F;&gt;&lt;b&gt;Completed&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT05029700?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","published_date":"2021-08-31T16:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":240,"discovery_date":"2021-08-31T15:55:07","title":"Safety Study to Evaluate Immune Response of Vaccines in Participants With Relapsing Forms of Multiple Sclerosis Who Receive Ozanimod Compared to Non-Pegylated Interferon (IFN)-β or No Disease Modifying Therapy","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Multiple Sclerosis;   Multiple Sclerosis, Relapsing-Remitting&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Biological: Tetanus, diphtheria, and acellular pertussis vaccine;   Biological: Pneumococcal polysaccharide vaccine;   Biological: Seasonal influenza vaccine&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Celgene&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT05028634?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","published_date":"2021-08-31T16:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":239,"discovery_date":"2021-08-31T02:48:29","title":"An Indian Multi-centric Phase IV Study to Assess the Safety of Crizanlizumab With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients With Vaso-occlusive Crises.","summary":"","link":"https://www.novartis.com/clinicaltrials/study/nct04662931","published_date":"","source":"Novartis","relevant":null,"table_constraints":null,"sent":1},{"trial_id":238,"discovery_date":"2021-08-31T02:48:29","title":"A 12-week Parallel Group, Randomized, Placebo-controlled, Double-blinded, Multi-center Study to Evaluate Efficacy and Safety of 2 Concentrations of SAF312 Eye Drops (5 mg&#x2F;ml and 15 mg&#x2F;ml) Used Twice-daily in the Treatment of Post-operative Corneal In ...","summary":"","link":"https://www.novartis.com/clinicaltrials/study/nct04630158","published_date":"","source":"Novartis","relevant":null,"table_constraints":null,"sent":1},{"trial_id":237,"discovery_date":"2021-08-27T18:48:30","title":"A Non-interventional Study to Assess the Influence of Automated Optical Coherence Tomography (OCT) Image Enrichment With Segmentation Information on Disease Activity Assessment in Patients Treated With Licensed Anti- VEGF Injections","summary":"","link":"https://www.novartis.com/clinicaltrials/study/nct04662944","published_date":"","source":"Novartis","relevant":null,"table_constraints":null,"sent":1},{"trial_id":236,"discovery_date":"2021-08-27T18:48:30","title":"A Prospective, 16 Week, Phase IV Study to Evaluate Safety, Tolerability and Effectiveness in Patients With Severe Dementia of the Alzheimer&#39;s Type Exposed to Rivastigmine (Exelon)15cm2 Transdermal Patch","summary":"","link":"https://www.novartis.com/clinicaltrials/study/nct02989402","published_date":"","source":"Novartis","relevant":null,"table_constraints":null,"sent":1},{"trial_id":235,"discovery_date":"2021-08-27T18:48:30","title":"A Phase III Multi-center, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET","summary":"","link":"https://www.novartis.com/clinicaltrials/study/nct03972488","published_date":"","source":"Novartis","relevant":null,"table_constraints":null,"sent":1},{"trial_id":234,"discovery_date":"2021-08-26T20:34:56","title":"Phase I, Open-label, Multicenter Study to Evaluate the Imaging Performance, Safety, Biodistribution and Dosimetry of [68Ga]-FF58 in Adult Patients With Selected Solid Tumors Expectedto Overexpress αvβ3 and αvβ5 Integrins.","summary":"","link":"https://www.novartis.com/clinicaltrials/study/nct04712721","published_date":"","source":"Novartis","relevant":null,"table_constraints":null,"sent":1},{"trial_id":233,"discovery_date":"2021-08-26T20:34:56","title":"Special Drug Use Surveillance for Entresto Tablets (Chronic Heart Failure, CLCZ696B1401)","summary":"","link":"https://www.novartis.com/clinicaltrials/study/nct04781881","published_date":"","source":"Novartis","relevant":null,"table_constraints":null,"sent":1},{"trial_id":232,"discovery_date":"2021-08-26T20:34:56","title":"Long Term Special Drug Use-results Surveillance for Mayzent in SPMS Patients (Prevention of Relapses and Delay of Progression of Physical Disability in Secondary Progressive Multiple Sclerosis)","summary":"","link":"https://www.novartis.com/clinicaltrials/study/nct04593927","published_date":"","source":"Novartis","relevant":null,"table_constraints":null,"sent":1},{"trial_id":231,"discovery_date":"2021-08-26T00:47:17","title":"Special Drug-use Surveillance for Kesimpta for s.c. Injection 20 mg Pen (Relapsing-remitting Multiple Sclerosis and Active Secondary Progressive Multiple Sclerosis)","summary":"","link":"https://www.novartis.com/clinicaltrials/study/nct04940065","published_date":"","source":"Novartis","relevant":null,"table_constraints":null,"sent":1},{"trial_id":230,"discovery_date":"2021-08-26T00:47:17","title":"A Phase III, Multicenter, Randomized, Double-blind Study to Assess Efficacy and Safety of Two Doses of Crizanlizumab Versus Placebo, With or Without Hydroxyurea&#x2F; Hydroxycarbamide Therapy, in Adolescent and Adult Sickle Cell Disease Patients With Vaso ...","summary":"","link":"https://www.novartis.com/clinicaltrials/study/nct03814746","published_date":"","source":"Novartis","relevant":null,"table_constraints":null,"sent":1},{"trial_id":229,"discovery_date":"2021-08-26T00:47:17","title":"A Three-period Multicenter Study, With a Randomized-withdrawal, Double-blinded, Placebo-controlled Design in Period 2 to Evaluate the Clinical Efficacy, Safety, and Tolerability of MAS825 in NLRC4-GOF Patients","summary":"","link":"https://www.novartis.com/clinicaltrials/study/nct04641442","published_date":"","source":"Novartis","relevant":null,"table_constraints":null,"sent":1},{"trial_id":228,"discovery_date":"2021-08-26T00:47:17","title":"A 12-week, Multicenter, Randomized, Double-blind, Parallel-arm, Placebo-controlled Study to Assess the Efficacy and Safety of CSJ117, When Added to Existing Asthma Therapy in Patients ≥ 18 Years of Age With Severe Uncontrolled Asthma.","summary":"","link":"https://www.novartis.com/clinicaltrials/study/nct04410523","published_date":"","source":"Novartis","relevant":null,"table_constraints":null,"sent":1},{"trial_id":227,"discovery_date":"2021-08-24T18:47:17","title":"A Randomized, Subject and Investigator Blinded, Placebo-controlled Multicenter Study to Assess the Efficacy and Safety of CMK389 in Patients With Moderate to Severe Atopic Dermatitis","summary":"","link":"https://www.novartis.com/clinicaltrials/study/nct04836858","published_date":"","source":"Novartis","relevant":null,"table_constraints":null,"sent":1},{"trial_id":226,"discovery_date":"2021-08-24T18:47:16","title":"EPIK-P2: A Phase II Double-blind Study With an Upfront, 16-week Randomized, Placebo-controlled Period, to Assess the Efficacy, Safety and Pharmacokinetics of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum ( ...","summary":"","link":"https://www.novartis.com/clinicaltrials/study/nct04589650","published_date":"","source":"Novartis","relevant":null,"table_constraints":null,"sent":1},{"trial_id":225,"discovery_date":"2021-08-24T18:47:16","title":"An Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care, Versus Standard of Care Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)","summary":"","link":"https://www.novartis.com/clinicaltrials/study/nct04720157","published_date":"","source":"Novartis","relevant":null,"table_constraints":null,"sent":1},{"trial_id":224,"discovery_date":"2021-08-24T18:47:16","title":"Phase Ib Study of Gevokizumab in Combination With Standard of Care Anti-cancer Therapies in Patients With Metastatic Colorectal Cancer, Gastroesophageal Cancer and Renal Cell Carcinoma","summary":"","link":"https://www.novartis.com/clinicaltrials/study/nct03798626","published_date":"","source":"Novartis","relevant":null,"table_constraints":null,"sent":1},{"trial_id":223,"discovery_date":"2021-08-24T13:43:55","title":"Immune Response to Seasonal Influenza Vaccination in Multiple Sclerosis Patients Receiving Cladribine","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Multiple Sclerosis, Relapsing-Remitting;   Vaccine Response Impaired&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Biological: Most recent vaccine to seasonal influenza&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Heinrich-Heine University, Duesseldorf&lt;br&#x2F;&gt;&lt;b&gt;Recruiting&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT05019248?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","published_date":"2021-08-24T16:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":222,"discovery_date":"2021-08-23T17:47:17","title":"Assessment of Prolonged Safety and tOLerability of in Migraine Patients in a Long-term OpeN-label Study","summary":"","link":"https://www.novartis.com/clinicaltrials/study/nct04084314","published_date":"","source":"Novartis","relevant":null,"table_constraints":null,"sent":1},{"trial_id":221,"discovery_date":"2021-08-23T17:47:17","title":"A Randomized, Placebo-controlled, Double-masked, Multi-center, Dose-ranging Study to Evaluate the Safety, and Efficacy of UNR844 in Subjects With Presbyopia","summary":"","link":"https://www.novartis.com/clinicaltrials/study/nct04806503","published_date":"","source":"Novartis","relevant":null,"table_constraints":null,"sent":1},{"trial_id":220,"discovery_date":"2021-08-23T12:23:55","title":"Swiss Pediatric Inflammatory Brain Disease Registry (Swiss-Ped-IBrainD)","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Optic Neuritis;   Transverse Myelitis;   Acute Disseminated Encephalomyelitis;   Multiple Sclerosis;   Neuromyelitis Optica Spectrum Disorder;   Anti-NMDAR Encephalitis;   Anti-GAD65 Associated Autoimmune Encephalitis;   Anti-AMPAR-1&#x2F;2 Associated Autoimmune Encephalitis;   Anti-Lgi-1 Associated Autoimmune Encephalitis;   Anti-CASPR-2 Associated Autoimmune Encephalitis;   Anti-GABAR-1&#x2F;2 Associated Autoimmune Encephalitis;   Onconeuronal Antibody (Hu, Ri, Yo, Amphiphysin, CRMP-5, Ma-1, Ma-2, SOX-1) Associated Autoimmune Encephalitis;   Hashimoto Encephalitis;   CNS Vasculitis;   CNS Sarcoidosis;   CNS Lupus;   Rasmussen Encephalitis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    &lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    University of Bern;   Schweizerische Multiple Sklerose Gesellschaft;   University Hospital Inselspital, Berne;   Roche Pharma (Switzerland) Ltd;   Novartis&lt;br&#x2F;&gt;&lt;b&gt;Recruiting&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT05017142?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","published_date":"2021-08-23T16:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":219,"discovery_date":"2021-08-23T12:23:55","title":"The Role of Social and Territorial Inequalities in the Management and Prognosis of Multiple Sclerosis","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Multiple Sclerosis;   Social and Territorial Inequalities&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    &lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Central Hospital, Nancy, France&lt;br&#x2F;&gt;&lt;b&gt;Recruiting&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT05017038?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","published_date":"2021-08-23T16:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":218,"discovery_date":"2021-08-19T22:19:09","title":"A Phase III Randomized, Double-blind, Placebo Controlled, Multicenter, Bridging Study of Subcutaneous Secukinumab, to Demonstrate Efficacy After Sixteen Weeks of Treatment and to Assess Safety, Tolerability and Long-term Efficacy Follow-up to One Yea ...","summary":"","link":"https://www.novartis.com/clinicaltrials/study/nct04711902","published_date":"","source":"Novartis","relevant":null,"table_constraints":null,"sent":1},{"trial_id":217,"discovery_date":"2021-08-19T22:19:09","title":"Digital Adherence Monitoring of Inhalative Therapy in Real- Life Conditions","summary":"","link":"https://www.novartis.com/clinicaltrials/study/nct04656223","published_date":"","source":"Novartis","relevant":null,"table_constraints":null,"sent":1},{"trial_id":216,"discovery_date":"2021-08-19T15:05:47","title":"Hydroxychloroquine and Indapamide in SPMS","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis, Secondary Progressive&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Drug: Hydroxychloroquine and Indapamide&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    University of Calgary&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT05013463?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","published_date":"2021-08-19T16:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":215,"discovery_date":"2021-08-19T15:05:47","title":"The Reliability of the Nine Hole Peg Test in Patients With Multiple Sclerosis","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Motor Activity&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Diagnostic Test: Nine Hole Peg Test&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Charles University, Czech Republic&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT05012241?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","published_date":"2021-08-19T16:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":214,"discovery_date":"2021-08-19T12:19:09","title":"An Open-label Multicenter Study to Assess Response to Influenza Vaccine in Participants With Multiple Sclerosis Treated With Ofatumumab 20 mg Subcutaneously","summary":"","link":"https://www.novartis.com/clinicaltrials/study/nct04667117","published_date":"","source":"Novartis","relevant":null,"table_constraints":null,"sent":1},{"trial_id":213,"discovery_date":"2021-08-19T12:19:09","title":"Tisagenlecleucel Versus Standard of Care in Adult Patients With Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma: A Randomized, Open Label, Phase III Trial (BELINDA)","summary":"","link":"https://www.novartis.com/clinicaltrials/study/nct03570892","published_date":"","source":"Novartis","relevant":null,"table_constraints":null,"sent":1},{"trial_id":212,"discovery_date":"2021-08-19T12:19:09","title":"A Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase III Multicenter Study of Intravenous Secukinumab to Compare Efficacy at 16 Weeks With Placebo and to Assess Safety and Tolerability up to 52 Weeks in Subjects With Active Ankylosin ...","summary":"","link":"https://www.novartis.com/clinicaltrials/study/nct04156620","published_date":"","source":"Novartis","relevant":null,"table_constraints":null,"sent":1},{"trial_id":211,"discovery_date":"2021-08-19T12:19:09","title":"A 52-week, Two Arm, Randomized, Open-label, Multicenter Study Assessing the Efficacy and Safety of Two Different Brolucizumab 6 mg Dosing Regimens for Patients With Suboptimal Anatomically Controlled Neovascular Age-related Macular Degeneration","summary":"","link":"https://www.novartis.com/clinicaltrials/study/nct04679935","published_date":"","source":"Novartis","relevant":null,"table_constraints":null,"sent":1},{"trial_id":210,"discovery_date":"2021-08-19T12:19:09","title":"A 5-year, Randomized, Double-blind, Placebo-controlled, Multi-center Study Assessing the Efficacy, Safety, and Tolerability of Intra-articular Regimens of LNA043 Versus Placebo in Patients With Symptomatic Knee Osteoarthritis","summary":"","link":"https://www.novartis.com/clinicaltrials/study/nct04864392","published_date":"","source":"Novartis","relevant":null,"table_constraints":null,"sent":1},{"trial_id":209,"discovery_date":"2021-08-19T07:19:09","title":"A Randomized, Open Label Multicenter Trial to Investigate the Efficacy of a Treat-to-target (T2T) Treatment Strategy With Secukinumab (AIN457) as a First-line Biologic Compared to a Standard-of-care (SOC) Treatment Over 36 Weeks in Patients With Acti ...","summary":"","link":"https://www.novartis.com/clinicaltrials/study/nct03906136","published_date":"","source":"Novartis","relevant":null,"table_constraints":null,"sent":1},{"trial_id":208,"discovery_date":"2021-08-19T02:19:10","title":"A Multi-center, Double-blinded and Open-label Extension Study to Evaluate the Efficacy and Safety of Ligelizumab as Retreatment, Self-administered Therapy and Monotherapy in Chronic Spontaneous Urticaria Patients Who Completed Studies CQGE031C2302, C ...","summary":"","link":"https://www.novartis.com/clinicaltrials/study/nct04210843","published_date":"","source":"Novartis","relevant":null,"table_constraints":null,"sent":1},{"trial_id":207,"discovery_date":"2021-08-19T02:19:10","title":"An Open-label, Multi-center Protocol for Patients Who Have Completed a Previous Novartis Sponsored Secukinumab Study and Are Judged by the Investigator to Benefit From Continued Secukinumab Treatment","summary":"","link":"https://www.novartis.com/clinicaltrials/study/nct04638647","published_date":"","source":"Novartis","relevant":null,"table_constraints":null,"sent":1},{"trial_id":206,"discovery_date":"2021-08-19T02:19:10","title":"A Multicenter, Double-blind, Randomized Withdrawal Extension Study of Subcutaneous Secukinumab to Demonstrate Long-term Efficacy, Safety and Tolerability in Subjects With Moderate to Severe Hidradenitis Suppurativa","summary":"","link":"https://www.novartis.com/clinicaltrials/study/nct04179175","published_date":"","source":"Novartis","relevant":null,"table_constraints":null,"sent":1},{"trial_id":205,"discovery_date":"2021-08-19T02:19:10","title":"A Phase IIIb Study of the Safety and Efficacy of Tisagenlecleucel Out of Specification for Commercial Release in Patients Who Are Consistent With the Label Indication","summary":"","link":"https://www.novartis.com/clinicaltrials/study/nct04094311","published_date":"","source":"Novartis","relevant":null,"table_constraints":null,"sent":1},{"trial_id":204,"discovery_date":"2021-08-19T02:19:10","title":"A Two-part, Randomized, Placebo-controlled, Patient and Investigator Blinded, Study Investigating the Safety, Tolerability and Preliminary Efficacy of Intra-articular LNA043 Injections in Regenerating the Articular Cartilage of the Knee in Patients W ...","summary":"","link":"https://www.novartis.com/clinicaltrials/study/nct03275064","published_date":"","source":"Novartis","relevant":null,"table_constraints":null,"sent":1},{"trial_id":203,"discovery_date":"2021-08-19T02:19:10","title":"A 12-month, Open-label, Multicenter, Randomized, Safety, Efficacy, Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of an Anti-CD40 Monoclonal Antibody, CFZ533 vs. Standard of Care Control, in Adult de Novo Liver Transplant Recipients With a 12-mo ...","summary":"","link":"https://www.novartis.com/clinicaltrials/study/nct03781414","published_date":"","source":"Novartis","relevant":null,"table_constraints":null,"sent":1},{"trial_id":202,"discovery_date":"2021-08-19T02:19:10","title":"A Randomized, Double-blind, Parallel-group, Multicenter Study to Assess Efficacy, Safety, and Tolerability of Oral Tropifexor (LJN452) &amp; Licogliflozin (LIK066) Combination Therapy and Each Monotherapy, Compared With Placebo for Treatment of Adult Pat ...","summary":"","link":"https://www.novartis.com/clinicaltrials/study/nct04065841","published_date":"","source":"Novartis","relevant":null,"table_constraints":null,"sent":1},{"trial_id":201,"discovery_date":"2021-08-19T02:19:10","title":"A Randomized, Double-blind, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab, to Compare Efficacy at 16 Weeks With Placebo and to Assess Safety and Tolerability up to 52 Weeks in Chinese Participants With Active Non-radiographic Axia ...","summary":"","link":"https://www.novartis.com/clinicaltrials/study/nct04732117","published_date":"","source":"Novartis","relevant":null,"table_constraints":null,"sent":1},{"trial_id":200,"discovery_date":"2021-08-19T02:19:10","title":"A Prospective Phase II, Open-Label, Single-arm, Multicenter, Study to Assess Efficacy and Safety of SEG101 (Crizanlizumab), in Sickle Cell Disease Patients With Priapism (SPARTAN)","summary":"","link":"https://www.novartis.com/clinicaltrials/study/nct03938454","published_date":"","source":"Novartis","relevant":null,"table_constraints":null,"sent":1},{"trial_id":199,"discovery_date":"2021-08-18T13:45:47","title":"Pregnancy Cohort in Multiple Sclerosis (MS)","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Multiple Sclerosis (MS);   Clinically Isolated Syndrome (CIS)&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    &lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Charite University, Berlin, Germany&lt;br&#x2F;&gt;&lt;b&gt;Recruiting&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT05010902?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","published_date":"2021-08-18T16:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":198,"discovery_date":"2021-08-17T20:19:09","title":"A 96-week, Two-arm, Randomized, Single-masked, Multi-center, Phase III Study Assessing the Efficacy and Safety of Brolucizumab 6 mg Compared to Panretinal Photocoagulation Laser in Patients With Proliferative Diabetic Retinopathy","summary":"","link":"https://www.novartis.com/clinicaltrials/study/nct04278417","published_date":"","source":"Novartis","relevant":null,"table_constraints":null,"sent":1},{"trial_id":197,"discovery_date":"2021-08-17T20:19:09","title":"A 64-week, Two-arm, Randomized, Double-masked, Multicenter, Phase IIIb Study Assessing the Efficacy and Safety of Brolucizumab 6 mg Compared to Aflibercept 2 mg in a Treat-to-control Regimen in Patients With Neovascular Agerelated Macular Degeneratio ...","summary":"","link":"https://www.novartis.com/clinicaltrials/study/nct04005352","published_date":"","source":"Novartis","relevant":null,"table_constraints":null,"sent":1},{"trial_id":196,"discovery_date":"2021-08-17T20:19:09","title":"A Phase I, Multicenter, Open-label Study of Oral ABL001 in Patients With Chronic Myelogenous Leukemia (CML) or Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ ALL)","summary":"","link":"https://www.novartis.com/clinicaltrials/study/nct02081378","published_date":"","source":"Novartis","relevant":null,"table_constraints":null,"sent":1},{"trial_id":195,"discovery_date":"2021-08-17T15:35:47","title":"DreaMS - Validation Study 1","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Device: dreaMS App R2.0&lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    Research Center for Clinical Neuroimmunology and Neuroscience Basel;   Healios AG;   University Hospital, Basel, Switzerland;   University of Basel;   Innosuisse - Swiss Innovation Agency;   Novartis Pharmaceuticals;   Hoffmann-La Roche&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT05009160?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","published_date":"2021-08-17T16:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":194,"discovery_date":"2021-08-17T00:19:09","title":"EPIK-O: A Phase III, Multi-center, Randomized (1:1), Open-label, Active-controlled, Study to Assess the Efficacy and Safety of Alpelisib (BYL719) in Combination With Olaparib as Compared to Single Agent Cytotoxic Chemotherapy, in Participants With no ...","summary":"","link":"https://www.novartis.com/clinicaltrials/study/nct04729387","published_date":"","source":"Novartis","relevant":null,"table_constraints":null,"sent":1},{"trial_id":193,"discovery_date":"2021-08-17T00:19:09","title":"A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Alpelisib (BYL719) in Combination With Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer With Either Phosphoinositi ...","summary":"","link":"https://www.novartis.com/clinicaltrials/study/nct04251533","published_date":"","source":"Novartis","relevant":null,"table_constraints":null,"sent":1},{"trial_id":192,"discovery_date":"2021-08-17T00:19:09","title":"A Prospective, Long-Term Registry of Patients With a Diagnosis of Spinal Muscular Atrophy (SMA)","summary":"","link":"https://www.novartis.com/clinicaltrials/study/nct04174157","published_date":"","source":"Novartis","relevant":null,"table_constraints":null,"sent":1},{"trial_id":191,"discovery_date":"2021-08-17T00:19:09","title":"A 48-week, 6-arm, Randomized, Double-blind, Placebo-controlled Multicenter Trial to Assess the Safety and Efficacy of Multiple CFZ533 Doses Administered Subcutaneously in Two Distinct Populations of Patients With Sjögren&#39;s Syndrome (TWINSS)","summary":"","link":"https://www.novartis.com/clinicaltrials/study/nct03905525","published_date":"","source":"Novartis","relevant":null,"table_constraints":null,"sent":1},{"trial_id":190,"discovery_date":"2021-08-17T00:19:09","title":"A 52-week Multicenter, Randomized, Double-masked, 2-arm Parallel Study to Compare Efficacy, Safety and Immunogenicity of SOK583A1 to Eylea®, Administered Intravitreally, in Patients With Neovascular Age-related Macular Degeneration","summary":"","link":"https://www.novartis.com/clinicaltrials/study/nct04864834","published_date":"","source":"Novartis","relevant":null,"table_constraints":null,"sent":1},{"trial_id":189,"discovery_date":"2021-08-16T17:25:47","title":"Efficacy of Diet on Quality of Life in Multiple Sclerosis","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis, Relapsing-Remitting&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Dietary Supplement: BodyBio Balance Oil;   Dietary Supplement: Kirunal Fish Oil;   Dietary Supplement: BodyBio PC;   Behavioral: Modified Paleolithic Elimination diet;   Behavioral: Time Restricted Olive Oil Based (TROO) Ketogenic Diet;   Behavioral: Dietary Guidelines for Americans Diet&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Terry L. Wahls&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT05007483?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","published_date":"2021-08-16T16:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":188,"discovery_date":"2021-08-13T16:19:09","title":"Open-Label Rater-Blind Randomized Multi-Center Parallel-Arm Active- Comparator Study to Assess the Efficacy and Tolerability of Ofatumumab 20mg SC Monthly vs. First Line DMT - Physician&#39;s Choice in the Treatment of Newly Diagnosed RMS","summary":"","link":"https://www.novartis.com/clinicaltrials/study/nct04788615","published_date":"","source":"Novartis","relevant":null,"table_constraints":null,"sent":1},{"trial_id":187,"discovery_date":"2021-08-13T13:25:47","title":"A Teleheath tDCS Approach to Decrease Cannabis Use","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Cannabis Use Disorder;   Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Other: Transcranial Direct Current Stimulation (tDCS);   Other: Sham - Transcranial Direct Current Stimulation (tDCS);   Other: Mindfulness&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    NYU Langone Health&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT05005013?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","published_date":"2021-08-13T16:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":186,"discovery_date":"2021-08-12T20:19:09","title":"A Phase III Multi-center, Randomized, Open-label Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as an Adjuvant Treatment in Patients With Hormone Receptor-positive, HER2-negative Early Breast Cancer (New Adjuvant TriAl Wit ...","summary":"","link":"https://www.novartis.com/clinicaltrials/study/nct03701334","published_date":"","source":"Novartis","relevant":null,"table_constraints":null,"sent":1},{"trial_id":185,"discovery_date":"2021-08-12T20:19:09","title":"An Open-label, Single Arm, Multi-center Extension Study Evaluating Long-term Safety, Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis","summary":"","link":"https://www.novartis.com/clinicaltrials/study/nct03650114","published_date":"","source":"Novartis","relevant":null,"table_constraints":null,"sent":1},{"trial_id":184,"discovery_date":"2021-08-12T15:19:08","title":"A Phase II Randomized Double-blind, Placebo-controlled Study of Alpelisib in Combination With Fulvestrant for Chinese Men and Postmenopausal Women With Hormone Receptor Positive, HER2-negative, PIK3CA Mutant Advanced Breast Cancer Which Progressed on ...","summary":"","link":"https://www.novartis.com/clinicaltrials/study/nct04544189","published_date":"","source":"Novartis","relevant":null,"table_constraints":null,"sent":1},{"trial_id":183,"discovery_date":"2021-08-12T15:19:08","title":"A Phase II, Open Label, Multi-center Trial to Determine the Efficacy and Safety of Tisagenlecleucel Re-infusion in Pediatric and Adolescent Young Adult (AYA) Patients With Acute Lymphoblastic Leukemia Experiencing Loss of B Cell Aplasia","summary":"","link":"https://www.novartis.com/clinicaltrials/study/nct04225676","published_date":"","source":"Novartis","relevant":null,"table_constraints":null,"sent":1},{"trial_id":182,"discovery_date":"2021-08-12T15:19:08","title":"A 2 Year, Double-blind, Randomized, Multicenter, Active-controlled Core Phase to Evaluate Safety &amp; Efficacy of Daily Fingolimod vs Weekly Interferon β-1a im in Pediatric Patients With Multiple Sclerosis and 5 Year Fingolimod Extension Phase","summary":"","link":"https://www.novartis.com/clinicaltrials/study/nct01892722","published_date":"","source":"Novartis","relevant":null,"table_constraints":null,"sent":1},{"trial_id":181,"discovery_date":"2021-08-12T15:19:08","title":"A Single-arm, Prospective, Multicentre, Open-label Study to Evaluate Ofatumumab Treatment Effectiveness and Patient Reported Outcomes in Patients With Relapsing Multiple Sclerosis Transitioning From Dimethyl Fumarate or Fingolimod Therapy","summary":"","link":"https://www.novartis.com/clinicaltrials/study/nct04353492","published_date":"","source":"Novartis","relevant":null,"table_constraints":null,"sent":1},{"trial_id":180,"discovery_date":"2021-08-12T15:09:11","title":"Exploring the Safety and Tolerability of Conversion From Oral, Injectable, or Infusion Disease Modifying Therapies to Dose-titrated Oral Siponimod (Mayzent) in Patients With Advancing Forms of Relapsing Multiple Sclerosis: A 6-month Open Label, Multi ...","summary":"","link":"https://www.novartis.com/clinicaltrials/study/nct03623243","published_date":"","source":"Novartis","relevant":null,"table_constraints":null,"sent":1},{"trial_id":179,"discovery_date":"2021-08-12T15:09:11","title":"A 24-month, Open-label, Prospective, Multicenter Interventional, Single-arm Study Assessing the Efficacy and Safety of Fingolimod (Gilenya) 0.5 mg in Relapsing Multiple Sclerosis (RMS) Patients in China","summary":"","link":"https://www.novartis.com/clinicaltrials/study/nct04667949","published_date":"","source":"Novartis","relevant":null,"table_constraints":null,"sent":1},{"trial_id":178,"discovery_date":"2021-08-12T15:09:11","title":"A Phase Ib&#x2F;II, Open Label Study of Sabatolimab as a Treatment for Patients With Acute Myeloid Leukemia and Presence of Measurable Residual Disease After Allogeneic Stem Cell Transplantation","summary":"","link":"https://www.novartis.com/clinicaltrials/study/nct04623216","published_date":"","source":"Novartis","relevant":null,"table_constraints":null,"sent":1},{"trial_id":177,"discovery_date":"2021-08-12T15:09:11","title":"A Randomized, Multicenter, Open-label Trial Comparing the Effectiveness of an &quot;Inclisiran First&quot; Implementation Strategy to Usual Care on LDL Cholesterol (LDL-C) in Patients With Atherosclerotic Cardiovascular Disease and Elevated LDL-C (≥70 mg&#x2F;dL) D ...","summary":"","link":"https://www.novartis.com/clinicaltrials/study/nct04929249","published_date":"","source":"Novartis","relevant":null,"table_constraints":null,"sent":1},{"trial_id":176,"discovery_date":"2021-08-12T15:09:11","title":"A Single-arm, Prospective, Multi-center Study to Explore Maintained Efficacy With Ofatumumab Therapy in Patients With Relapsing Multiple Sclerosis Who Discontinue Intravenously Delivered Anti-CD20 Monoclonal Antibody (aCD20 mAb) Therapy (OLIKOS)","summary":"","link":"https://www.novartis.com/clinicaltrials/study/nct04486716","published_date":"","source":"Novartis","relevant":null,"table_constraints":null,"sent":1},{"trial_id":175,"discovery_date":"2021-08-12T15:09:11","title":"An Open Label, Multi-center Phase IIIb Study of Asciminib (ABL001) Monotherapy in Previously Treated Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With and Without T315I Mutation","summary":"","link":"https://www.novartis.com/clinicaltrials/study/nct04666259","published_date":"","source":"Novartis","relevant":null,"table_constraints":null,"sent":1},{"trial_id":174,"discovery_date":"2021-08-12T15:09:11","title":"A 12-week Phase 3, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Once Monthly Subcutaneous Erenumab 70 mg in Adult Chronic Migraine Patients","summary":"","link":"https://www.novartis.com/clinicaltrials/study/nct03867201","published_date":"","source":"Novartis","relevant":null,"table_constraints":null,"sent":1},{"trial_id":173,"discovery_date":"2021-08-12T15:09:11","title":"A Randomized, Double-blind, Placebo-controlled Phase III Multi-center Study of Azacitidine With or Without MBG453 for the Treatment of Patients With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomo ...","summary":"","link":"https://www.novartis.com/clinicaltrials/study/nct04266301","published_date":"","source":"Novartis","relevant":null,"table_constraints":null,"sent":1},{"trial_id":172,"discovery_date":"2021-08-12T15:09:11","title":"A Randomized, Participant, Investigator and Sponsor Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of Intrathecally Administered NIO752 in Participants With Progressive Supranuc ...","summary":"","link":"https://www.novartis.com/clinicaltrials/study/nct04539041","published_date":"","source":"Novartis","relevant":null,"table_constraints":null,"sent":1},{"trial_id":171,"discovery_date":"2021-08-12T15:09:11","title":"An Open-label Multicenter Study to Assess Response to COVID-19 Vaccine in Participants With Multiple Sclerosis Treated With Ofatumumab 20 mg Subcutaneously","summary":"","link":"https://www.novartis.com/clinicaltrials/study/nct04878211","published_date":"","source":"Novartis","relevant":null,"table_constraints":null,"sent":1},{"trial_id":170,"discovery_date":"2021-08-12T13:29:25","title":"Physiological Responses in Experimentally Induced Cognitive Fatigue in People With Multiple Sclerosis (MS)","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Multiple Sclerosis;   Fatigue;   Stress&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Behavioral: High-challenging cognitive protocol to provoke stress and (cognitive) fatigue&lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    KU Leuven;   National MS Center Melsbroek&lt;br&#x2F;&gt;&lt;b&gt;Recruiting&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT05003375?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","published_date":"2021-08-12T16:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":169,"discovery_date":"2021-08-12T13:29:25","title":"Efficacy of Cognitive Behavioral Therapy on Fatigue, Cognition and Inflammatory Biomarkers in MS Patients","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Device: &quot;RehaCom&quot; computer-based cognitive training in addition to Conventional physical therapy program;   Other: Conventional physical therapy program&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Cairo University&lt;br&#x2F;&gt;&lt;b&gt;Completed&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT05002062?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","published_date":"2021-08-12T16:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":168,"discovery_date":"2021-08-12T13:29:25","title":"Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for MS","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Biological: AlloRx&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    The Foundation for Orthopaedics and Regenerative Medicine&lt;br&#x2F;&gt;&lt;b&gt;Recruiting&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT05003388?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","published_date":"2021-08-12T16:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":167,"discovery_date":"2021-08-12T13:29:25","title":"Thalamic Nuclei Volumes in Multiple Sclerosis","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    &lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    University Hospital, Bordeaux;   Institut National de la Santé Et de la Recherche Médicale, France&lt;br&#x2F;&gt;&lt;b&gt;Recruiting&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT05002764?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","published_date":"2021-08-12T16:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":166,"discovery_date":"2021-08-11T15:21:39","title":"COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Rheumatoid Arthritis;   Systemic Lupus Erythematosus (SLE);   Pemphigus Vulgaris;   Multiple Sclerosis;   Systemic Sclerosis (SSc)&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Biological: Moderna mRNA-1273;   Biological: BNT162b2;   Biological: Ad26.COV2.S;   Drug: IS (MMF or MPA);   Drug: IS (MTX);   Biological: IS (B cell depletion therapy)&lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    National Institute of Allergy and Infectious Diseases (NIAID);   Autoimmunity Centers of Excellence;   Rho Federal Systems Division, Inc.&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT05000216?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","published_date":"2021-08-11T16:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":165,"discovery_date":"2021-08-10T14:01:41","title":"A Study Evaluating B Cell Levels In Infants Potentially Exposed To Ocrelizumab During Pregnancy","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Multiple Sclerosis;   Clinically Isolated Syndrome&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Drug: Ocrelizumab&lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    Hoffmann-La Roche;   PPD;   LabCorp;   Illingworth&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT04998812?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","published_date":"2021-08-10T16:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":164,"discovery_date":"2021-08-10T14:01:41","title":"A Study Evaluating B Cell Levels In Infants Of Lactating Women With CIS Or MS Receiving Ocrelizumab","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Multiple Sclerosis;   Clinically Isolated Syndrome&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Drug: Ocrelizumab&lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    Hoffmann-La Roche;   PPD;   LabCorp;   Illingworth&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT04998851?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","published_date":"2021-08-10T16:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":163,"discovery_date":"2021-08-09T12:36:29","title":"Symptoms and Treatment Assessment of Ano-Rectal Disorders in Multiple Sclerosis Patients : STAR-Q","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Multiple Sclerosis;   Constipation;   Fecal Incontinence&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Other: Clinical interviews&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Pierre and Marie Curie University&lt;br&#x2F;&gt;&lt;b&gt;Completed&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT04996186?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","published_date":"2021-08-09T16:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":162,"discovery_date":"2021-08-09T12:36:29","title":"Neurophysiological Assessment in Patients With Multiple Sclerosis","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Multiple Sclerosis;   Demyelinating Disease;   Inflammatory Disease&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Other: Neurophysiological assessment;   Other: clinical assessment&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    University of Roma La Sapienza&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT04997343?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","published_date":"2021-08-09T16:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":161,"discovery_date":"2021-08-09T12:36:29","title":"Effectiveness of Cladribine Tablets in Participants With Highly-active Relapsing Multiple Sclerosis (CAMELOT-MS)","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Relapsing-Remitting Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    &lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany;   Merck Serono Limited, an affiliate of Merck KGaA, Darmstadt, Germany&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT04997148?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","published_date":"2021-08-09T16:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":160,"discovery_date":"2021-08-07T00:23:03","title":"A Phase 1, Open-label, Single-dose, Parallel-group Study to Evaluate the Systemic Pharmacokinetics of Icenticaftor in Participants With Mild, Moderate, or Severe Hepatic Impairment Compared to Matched Healthy Control Participants","summary":"","link":"https://www.novartis.com/clinicaltrials/study/nct04587622","published_date":"","source":"Novartis","relevant":null,"table_constraints":null,"sent":1},{"trial_id":159,"discovery_date":"2021-08-07T00:23:03","title":"A First-in-patient Phase I&#x2F;II Clinical Study to Investigate the Safety, Tolerability and Efficacy of Genome-edited Hematopoietic Stem and Progenitor Cells in Subjects With Severe Complications of Sickle Cell Disease","summary":"","link":"https://www.novartis.com/clinicaltrials/study/nct04443907","published_date":"","source":"Novartis","relevant":null,"table_constraints":null,"sent":1},{"trial_id":158,"discovery_date":"2021-08-06T12:10:36","title":"Sensitivity of Motor Assessment in MS - a Prospective Cohort Study","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Multiple Sclerosis, Relapsing-Remitting;   Multiple Sclerosis, Secondary Progressive;   Multiple Sclerosis, Chronic Progressive&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Diagnostic Test: PASS-MS&lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    Friedemann Paul;   Roche Pharma AG&lt;br&#x2F;&gt;&lt;b&gt;Active, not recruiting&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT04993274?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","published_date":"2021-08-06T16:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":157,"discovery_date":"2021-08-06T12:10:36","title":"Quantitative T1rho Magnetic Resonance Imaging in Multiple Sclerosis (MS)","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Multiple Sclerosis;   Magnetic Resonance Imaging&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Diagnostic Test: T1rho imaging&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Chinese University of Hong Kong&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT04993196?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","published_date":"2021-08-06T16:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":156,"discovery_date":"2021-08-05T22:46:35","title":"An Open-label, Adaptive Design Study in Patients With Amyotrophic Lateral Sclerosis (ALS) to Characterize Safety, Tolerability and Brain Microglia Response, as Measured by TSPO Binding, Following Multiple Doses of BLZ945 Using Positron Emission Tomog ...","summary":"","link":"https://www.novartis.com/clinicaltrials/study/nct04066244","published_date":"","source":"Novartis","relevant":null,"table_constraints":null,"sent":1},{"trial_id":155,"discovery_date":"2021-08-05T22:46:35","title":"An Open-label, Two-period, Single-sequence, Crossover Study to Compare the Systemic Exposure of a Single Inhaled Dose of Mometasone Furoate (MF) When Administered Alone Via the MF Twisthaler® (TH) to a Single Inhaled Dose of QMF149 Indacaterol Acetat ...","summary":"","link":"https://www.novartis.com/clinicaltrials/study/nct04589663","published_date":"","source":"Novartis","relevant":null,"table_constraints":null,"sent":1},{"trial_id":154,"discovery_date":"2021-08-05T22:46:35","title":"A Double-blind, Placebo-controlled, Randomized Dose-ranging Trial to Investigate Efficacy and Safety of Intravenous MIJ821 Infusion in Addition to Comprehensive Standard of Care on the Rapid Reduction of Symptoms of Major Depressive Disorder in Subje ...","summary":"","link":"https://www.novartis.com/clinicaltrials/study/nct04722666","published_date":"","source":"Novartis","relevant":null,"table_constraints":null,"sent":1},{"trial_id":153,"discovery_date":"2021-08-05T22:46:35","title":"A Subject and Investigator Blinded, Randomized, Placebo-controlled, Repeat-dose, Multicenter Study to Investigate Efficacy, Safety, and Tolerability of CMK389 in Patients With Chronic Pulmonary Sarcoidosis","summary":"","link":"https://www.novartis.com/clinicaltrials/study/nct04064242","published_date":"","source":"Novartis","relevant":null,"table_constraints":null,"sent":1},{"trial_id":152,"discovery_date":"2021-08-05T22:46:35","title":"A Randomized, Subject and Investigator Blinded, Placebo Controlled, Multi-center Study in Parallel Groups to Assess the Efficacy and Safety of LYS006 in Patients With Moderate to Severe Inflammatory Acne","summary":"","link":"https://www.novartis.com/clinicaltrials/study/nct03497897","published_date":"","source":"Novartis","relevant":null,"table_constraints":null,"sent":1},{"trial_id":151,"discovery_date":"2021-08-05T22:46:35","title":"A Phase II Trial of Tisagenlecleucel in First-line High-risk (HR) Pediatric and Young Adult Patients With B-cell Acute Lymphoblastic Leukemia (B-ALL) Who Are Minimal Residual Disease (MRD) Positive at the End of Consolidation (EOC) Therapy","summary":"","link":"https://www.novartis.com/clinicaltrials/study/nct03876769","published_date":"","source":"Novartis","relevant":null,"table_constraints":null,"sent":1},{"trial_id":150,"discovery_date":"2021-08-05T15:59:12","title":"Pronesimod no tratamento de Esclerose Múltipla Recidivante","summary":"","link":"https://www.cuf.pt/cuf-academic-center/ensaios-clinicos/pronesimod-no-tratamento-de-esclerose-multipla-recidivante","published_date":"","source":"CUF","relevant":null,"table_constraints":null,"sent":1},{"trial_id":149,"discovery_date":"2021-08-05T15:53:54","title":"PSMAfore: A Phase III, Open-label, Multi-Center, Randomized Study Comparing 177Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in the Treatment of Taxane Naïve Men With Progressive Metastatic Castrate Resistant Prostate Cancer","summary":"","link":"https://www.novartis.com/clinicaltrials/study/nct04689828","published_date":"","source":"Novartis","relevant":null,"table_constraints":null,"sent":1},{"trial_id":148,"discovery_date":"2021-08-05T15:39:00","title":"A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase III Study to Evaluate the Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients","summary":"","link":"https://www.novartis.com//clinicaltrials/study/nct04578834","published_date":"","source":"Novartis","relevant":null,"table_constraints":null,"sent":1},{"trial_id":147,"discovery_date":"2021-08-05T15:39:00","title":"An Open-label, Non-randomized Extension Study to Evaluate the Long Term Safety, Tolerability, Efficacy and Pharmacokinetics of CDZ173 in Patients With APDS&#x2F;PASLI (Activated Phosphoinositide 3-kinase Delta Syndrome&#x2F;p110δ-activating Mutation Causing Se ...","summary":"","link":"https://www.novartis.com//clinicaltrials/study/nct02859727","published_date":"","source":"Novartis","relevant":null,"table_constraints":null,"sent":1},{"trial_id":146,"discovery_date":"2021-08-05T15:39:00","title":"An Open-label, Single Arm Phase II Study of DFV890 to Assess the Safety, Tolerability and Efficacy in Participants With Familial Cold Auto-inflammatory Syndrome (FCAS)","summary":"","link":"https://www.novartis.com//clinicaltrials/study/nct04868968","published_date":"","source":"Novartis","relevant":null,"table_constraints":null,"sent":1},{"trial_id":145,"discovery_date":"2021-08-05T15:39:00","title":"A 24-week Multi-center, Double-blind, Placebo Controlled Dose-range Finding Study to Investigate the Efficacy and Safety of Oral QBW251 in COPD Patients on Triple Inhaled Therapy (LABA &#x2F; LAMA &#x2F; ICS)","summary":"","link":"https://www.novartis.com//clinicaltrials/study/nct04072887","published_date":"","source":"Novartis","relevant":null,"table_constraints":null,"sent":1},{"trial_id":144,"discovery_date":"2021-08-05T15:39:00","title":"A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease","summary":"","link":"https://www.novartis.com//clinicaltrials/study/nct04023552","published_date":"","source":"Novartis","relevant":null,"table_constraints":null,"sent":1},{"trial_id":143,"discovery_date":"2021-08-05T15:39:00","title":"A Randomized, Placebo-controlled, Investigator- and Participant-blinded Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of HSY244 in Participants With Atrial Fibrillation","summary":"","link":"https://www.novartis.com//clinicaltrials/study/nct04582409","published_date":"","source":"Novartis","relevant":null,"table_constraints":null,"sent":1},{"trial_id":142,"discovery_date":"2021-08-05T15:39:00","title":"A Randomized, Controlled, Multicenter, Open-label Trial Comparing a Hospital Post-discharge Care Pathway Involving Aggressive LDL-C Management That Includes Inclisiran With Usual Care Versus Usual Care Alone in Patients With a Recent Acute Coronary S ...","summary":"","link":"https://www.novartis.com//clinicaltrials/study/nct04873934","published_date":"","source":"Novartis","relevant":null,"table_constraints":null,"sent":1},{"trial_id":141,"discovery_date":"2021-08-05T15:39:00","title":"A Randomized, Multicenter, Active-comparator Controlled, Open-label Trial to Evaluate Efficacy and Safety of Oral, Twice Daily LNP023 in Adult Patients With PNH and Residual Anemia, Despite Treatment With an Intravenous Anti-C5 Antibody.","summary":"","link":"https://www.novartis.com//clinicaltrials/study/nct04558918","published_date":"","source":"Novartis","relevant":null,"table_constraints":null,"sent":1},{"trial_id":140,"discovery_date":"2021-08-05T15:39:00","title":"Multi-center Cross-sectional Epidemiological Study to Characterize the Prevalence and Distribution of Lipoprotein(a) Levels Among Patients With Established Cardiovascular Disease","summary":"","link":"https://www.novartis.com//clinicaltrials/study/nct03887520","published_date":"","source":"Novartis","relevant":null,"table_constraints":null,"sent":1},{"trial_id":139,"discovery_date":"2021-08-05T15:39:00","title":"Two Part (Double-blind Inclisiran Versus Placebo [Year 1] Followed by Open-label Inclisiran [Year 2]) Randomized Multicenter Study to Evaluate Safety, Tolerability, and Efficacy of Inclisiran in Adolescents (12 to Less Than 18 Years) With Heterozygou ...","summary":"","link":"https://www.novartis.com//clinicaltrials/study/nct04652726","published_date":"","source":"Novartis","relevant":null,"table_constraints":null,"sent":1},{"trial_id":138,"discovery_date":"2021-08-05T15:39:00","title":"","summary":"","link":"https://www.novartis.com/","published_date":"","source":"Novartis","relevant":null,"table_constraints":null,"sent":1},{"trial_id":137,"discovery_date":"2021-08-05T15:39:00","title":"More locations","summary":"","link":"https://www.novartis.com/","published_date":"","source":"Novartis","relevant":null,"table_constraints":null,"sent":1},{"trial_id":136,"discovery_date":"2021-08-04T13:22:57","title":"Territorial Implementation and Evaluation of a Multiple Sclerosis Expert Patient Program","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Multiple Sclerosis;   Quality of Life;   Patient Empowerment;   Patient Activation;   Fatigue;   Peer Group&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Other: Multiple Sclerosis Expert Patient Program of Catalonia&lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    Hospital Universitari Vall d&#39;Hebron Research Institute;   Strategic Plan for Research and Innovation in Health (ref. BDNS 542793)&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT04988880?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","published_date":"2021-08-04T16:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":135,"discovery_date":"2021-08-04T13:22:57","title":"A Study of Lu AG06466 for the Treatment of Spasticity in Participants With Multiple Sclerosis","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Drug: Lu AG06466;   Drug: Placebo&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    H. Lundbeck A&#x2F;S&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT04990219?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","published_date":"2021-08-04T16:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":134,"discovery_date":"2021-07-30T17:01:11","title":"Evaluation of the Effect of Nabiximols Oromucosal Spray on Clinical Measures of Spasticity in Participants With Multiple Sclerosis","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Spasticity With Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Drug: Nabiximols;   Drug: Placebo&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    GW Pharmaceuticals Ltd.&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT04984278?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","published_date":"2021-07-30T16:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":133,"discovery_date":"2021-07-29T14:28:11","title":"Single Ascending Dose Study of SAR443820 in Healthy Adult Chinese and Japanese Female and Male Participants","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis Healthy Subjects&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Drug: RIPK1 inhibitor&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Sanofi&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT04982991?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","published_date":"2021-07-29T16:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":132,"discovery_date":"2021-07-28T18:48:11","title":"Telerehabilitation in Multiple Sclerosis","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Other: Telerehabilitation;   Other: Video exercise&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Marmara University&lt;br&#x2F;&gt;&lt;b&gt;Recruiting&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT04979845?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","published_date":"2021-07-28T16:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":131,"discovery_date":"2021-07-28T18:48:11","title":"Corticosteroid Effects on Asymptomatic Gadolinium-enhancing Lesions in Multiple Sclerosis","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Multiple Sclerosis, Relapsing-Remitting;   Magnetic Resonance Imaging;   Methylprednisolone&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Drug: Methylprednisolone succinate&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Mazandaran University of Medical Sciences&lt;br&#x2F;&gt;&lt;b&gt;Enrolling by invitation&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT04979650?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","published_date":"2021-07-28T16:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":130,"discovery_date":"2021-07-28T18:48:11","title":"Using Patient-Reported Outcomes To Improve the Care of People With Multiple Sclerosis","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Multiple Sclerosis;   Anxiety;   Depression;   Patient Satisfaction&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Other: Intensive Use of Patient Reported Outcome Measures and Open PROM Availability to Treating Neurologist;   Other: Conservative Use of Patient Reported Outcome Measures and Blinded PROM Availability to Treating Neurologist&lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    University of Alberta;   University Hospital Foundation&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT04979546?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","published_date":"2021-07-28T16:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":129,"discovery_date":"2021-07-28T18:48:11","title":"The Validity and Reliability of the Upper Extremity Exercise Testing (UULEX) in Patients With Multiple Sclerosis","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Other: Upper extremity endurance test (UULEX)&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Marmara University&lt;br&#x2F;&gt;&lt;b&gt;Recruiting&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT04979819?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","published_date":"2021-07-28T16:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":128,"discovery_date":"2021-07-27T15:16:12","title":"Gray Matter Demyelination in Primary Progressive MS at 7T","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Primary Progressive Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    &lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    Danish Research Centre for Magnetic Resonance;   Scleroseforeningen;   Danish Multiple Sclerosis Center&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT04977622?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","published_date":"2021-07-27T16:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":127,"discovery_date":"2021-07-23T12:56:11","title":"Strengthening Mental Abilities With Relational Training (SMART) in Multiple Sclerosis (MS): A Feasibility Trial","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Behavioral: SMART;   Behavioral: Sham brain training (Sudoku)&lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    University of Lincoln;   University of Exeter;   Nottinghamshire Healthcare NHS Trust;   National University of Ireland, Maynooth;   University of Nottingham&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT04975685?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","published_date":"2021-07-23T16:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":126,"discovery_date":"2021-07-22T17:03:44","title":"Effects of Chiropractic Care on Cytokine Levels in Multiple Sclerosis","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis, Relapsing-Remitting&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Other: Spinal Manipulation;   Other: Sham Spinal Manipulation&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    University of Alabama at Birmingham&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT04972929?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","published_date":"2021-07-22T16:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":125,"discovery_date":"2021-07-22T17:03:44","title":"Functional Disorders of the Musculoskeletal System in People With Multiple Sclerosis","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Multiple Sclerosis;   Rehabilitation;   Musculoskeletal Complication&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Behavioral: Manual physiotherapeutic correction (MFK) Method;   Behavioral: Dynamic Neuromuscular Stabilization (DNS) Method&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Charles University, Czech Republic&lt;br&#x2F;&gt;&lt;b&gt;Completed&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT04973501?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","published_date":"2021-07-22T16:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":124,"discovery_date":"2021-07-21T12:32:44","title":"Ocrelizumab or Alemtuzumab Compared With Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis - a Phase-2 Randomised Controlled Trial","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Relapsing-Remitting Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Drug: Autologous Hematopoietic Stem Cell Transplantation;   Drug: Ocrelizumab;   Drug: Alemtuzumab&lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    Universitätsklinikum Hamburg-Eppendorf;   Neovii Biotech;   Clinical Trial Center North (CTC North GmbH &amp; Co. KG)&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT04971005?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","published_date":"2021-07-21T16:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":123,"discovery_date":"2021-07-21T12:32:44","title":"Quantifying Gait Alteration in Multiple Sclerosis Using a Wearable Device","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Other: Wearable sensor&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Nantes University Hospital&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT04969848?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","published_date":"2021-07-21T16:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":122,"discovery_date":"2021-07-20T13:49:06","title":"The Effect of Emotional Freedom Technique on Depression, Anxiety and Distress of Individuals With Multiple Sclerosis","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Multiple Sclerosis;   Anxiety;   Depressive Symptoms;   Distress;   Psychiatric Nursing&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Behavioral: Emotional Freedom Technique&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Dokuz Eylul University&lt;br&#x2F;&gt;&lt;b&gt;Recruiting&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT04969562?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","published_date":"2021-07-20T16:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":121,"discovery_date":"2021-07-19T12:15:08","title":"Efficacy and Safety of Xacrel® (Ocrelizumab) in Participants With Relapsing Remitting Multiple Sclerosis","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Multiple Sclerosis;   Relapsing-Remitting&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Biological: Ocrelizumab (CinnaGen, Iran);   Biological: Ocrelizumab (Roche, Switzerland)&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Cinnagen&lt;br&#x2F;&gt;&lt;b&gt;Active, not recruiting&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT04966338?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","published_date":"2021-07-19T16:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":120,"discovery_date":"2021-07-16T13:27:06","title":"An Observational Study to Investigate the Role of B Cells in Multiple Sclerosis","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Other: Analysis of B cells&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    University of Oslo&lt;br&#x2F;&gt;&lt;b&gt;Recruiting&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT04964336?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","published_date":"2021-07-16T16:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":119,"discovery_date":"2021-07-16T13:27:06","title":"Analysis of MS Patients Who Have Had Greater Than 60 Infusions of Natalizumab","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Drug: Natalizumab&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Multiple Sclerosis Center of Northeastern New York&lt;br&#x2F;&gt;&lt;b&gt;Active, not recruiting&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT04964700?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","published_date":"2021-07-16T16:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":118,"discovery_date":"2021-07-16T13:27:06","title":"RMS Study of BTK Inhibitor SAR442168","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Relapsing Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Drug: SAR442168&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Peking University Third Hospital&lt;br&#x2F;&gt;&lt;b&gt;Recruiting&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT04964791?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","published_date":"2021-07-16T16:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":117,"discovery_date":"2021-07-15T12:52:04","title":"Effects of a User-centered Exergame Training on Motor and Cognitive Functions in PwMS","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Behavioral: Exergame Training&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Eling DeBruin&lt;br&#x2F;&gt;&lt;b&gt;Recruiting&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT04963335?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","published_date":"2021-07-15T16:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":116,"discovery_date":"2021-07-09T11:20:04","title":"A Study to Evaluate the Safety, Tolerability, and Exploratory Efficacy of IMS001 in Subjects With Multiple Sclerosis","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Biological: IMS001&lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    ImStem Biotechnology;   Rho, Inc.&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT04956744?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","published_date":"2021-07-09T16:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":115,"discovery_date":"2021-07-08T14:32:36","title":"Technology-assisted Conscientiousness Therapy for People With Multiple Sclerosis","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Behavioral: Conscientiousness Coach&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    State University of New York at Buffalo&lt;br&#x2F;&gt;&lt;b&gt;Recruiting&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT04953689?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","published_date":"2021-07-08T16:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":114,"discovery_date":"2021-07-07T11:59:36","title":"Clinical Isolation Syndrome of Spinal Cord and Multiple Sclerosis","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Clinical Isolation Syndrome of Spinal Cord;   Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    &lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Peking University Third Hospital&lt;br&#x2F;&gt;&lt;b&gt;Recruiting&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT04952246?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","published_date":"2021-07-07T16:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":113,"discovery_date":"2021-07-07T11:59:36","title":"Study Evaluating SARS-CoV-2 (COVID-19) Humoral Response After BNT162b2 Vaccine in Immunocompromised Adults Compared to Healthy Adults","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Kidney Transplant;   Extracorporeal Dialysis;   Myeloma;   Cancer;   Hematologic Malignancy;   Multiple Sclerosis;   Hypergammaglobulinemia;   Malignant Tumor;   Hiv;   Diabetes Type 2&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Biological: Biological samples&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Centre Hospitalier Régional d&#39;Orléans&lt;br&#x2F;&gt;&lt;b&gt;Recruiting&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT04952766?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","published_date":"2021-07-07T16:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":112,"discovery_date":"2021-06-29T16:46:42","title":"CONNECT Trial of eSupport Online Health-coach Moderated Support Groups for PwMS","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Behavioral: eSupport Health Weekly Group Sessions for PwMS&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    eSupport Health&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT04943887?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","published_date":"2021-06-29T16:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":111,"discovery_date":"2021-06-29T16:46:42","title":"Impact of Direct Current Electrical Stimulation on Spasticity Levels and Functional Muscle Use in MS","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Device: NeuBie&lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    Centura Health;   NeuFit - Neurological Fitness and Education&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT04942938?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","published_date":"2021-06-29T16:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":110,"discovery_date":"2021-06-29T16:46:42","title":"Intrathecal Administration of DUOC-01 in Adults With Primary Progressive Multiple Sclerosis","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Primary Progressive Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Biological: DUOC-01&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Joanne Kurtzberg, MD&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT04943289?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","published_date":"2021-06-29T16:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":109,"discovery_date":"2021-06-29T16:46:42","title":"Regular Exercise Improves Physical Capacity and Promotes Neurotrophins in Patients With Multiple Sclerosis","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Multiple Sclerosis;   Exercise Intervention;   Neuro-Degenerative Disease&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Behavioral: Regular Exercise&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Ege University&lt;br&#x2F;&gt;&lt;b&gt;Completed&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT04944251?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","published_date":"2021-06-29T16:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":108,"discovery_date":"2021-06-28T16:23:24","title":"PET Study to Determine the Relationship Between Plasma Concentrations and Muscarinic Type 1 Receptor (M1AChR) Occupancy of PIPE-307 in Healthy Volunteers","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Drug: PIPE-307&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Pipeline Therapeutics, Inc.&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT04941781?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","published_date":"2021-06-28T16:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":107,"discovery_date":"2021-06-25T20:40:29","title":"Special Drug-use Surveillance for Kesimpta for s.c. Injection 20 mg Pen","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Relapsing-remitting Multiple Sclerosis;   Active Secondary Progressive Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Other: Kesimpta&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Novartis Pharmaceuticals&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT04940065?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","published_date":"2021-06-25T16:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":106,"discovery_date":"2021-06-24T16:09:29","title":"Reading Problems Associated With Central Nervous System (CNS) Pathologies.","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Injury Brain;   Eye Abnormalities;   Multiple Sclerosis;   Parkinson Disease;   Ataxia, Cerebellar&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Diagnostic Test: eye tracking&lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA;   Hospital Clínico Universitario de Valladolid;   Hospital del Río Hortega&lt;br&#x2F;&gt;&lt;b&gt;Enrolling by invitation&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT04937725?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","published_date":"2021-06-24T16:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":105,"discovery_date":"2021-06-23T16:33:29","title":"The Effect of Self-Acupressure Application on Functional Composite and Quality of Life in Multiple Sclerosis Patients","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Other: Self-Acupressure&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Istanbul Sabahattin Zaim University&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT04936555?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","published_date":"2021-06-23T16:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":104,"discovery_date":"2021-06-22T14:45:49","title":"Prospective Effectiveness and Safety Study of Cladribine in Participants Who Change First-line DMD Treatments for Multiple Sclerosis (CLAD CROSS)","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Drug: Cladribine&lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany;   Merck Hellas sa., Greece&lt;br&#x2F;&gt;&lt;b&gt;Recruiting&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT04934800?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","published_date":"2021-06-22T16:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":103,"discovery_date":"2021-06-21T20:04:49","title":"Investigation of Hand Functions and Related Parameters in People With Multiple Sclerosis","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    &lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    Uğur OVACIK;   Istanbul University-Cerrahpasa&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT04933110?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","published_date":"2021-06-21T16:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":102,"discovery_date":"2021-06-21T20:04:49","title":"Tele-Assessment and Face-to-Face Evaluation of Functional Gait Assessment in Multiple Sclerosis","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    &lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Istanbul University-Cerrahpasa&lt;br&#x2F;&gt;&lt;b&gt;Recruiting&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT04932616?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","published_date":"2021-06-21T16:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":101,"discovery_date":"2021-06-21T20:04:49","title":"Post-Authorization Safety Study for Assessment of Pregnancy Outcomes in Patients Treated With Mayzent","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Other: Siponimod&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Novartis Pharmaceuticals&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT04933552?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","published_date":"2021-06-21T16:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":100,"discovery_date":"2021-06-18T22:15:49","title":"Feasibility of Neuromodulation With Connectivity-Guided iTBS for Cognitive Impairment in MS","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Multiple Sclerosis;   Cognitive Impairment&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Other: Intermittent theta burst stimulation (iTBS);   Other: Sham Intermittent theta burst stimulation (iTBS)&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    University of Nottingham&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT04931953?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","published_date":"2021-06-18T16:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":99,"discovery_date":"2021-06-18T22:15:49","title":"Description of Adherence to the Main Preventive Health Campaigns of Persons With Multiple Sclerosis","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Other: phone interview&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    University of Siena&lt;br&#x2F;&gt;&lt;b&gt;Recruiting&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT04930380?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","published_date":"2021-06-18T16:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":98,"discovery_date":"2021-06-18T22:15:49","title":"The Gut Microbiome in Adult Multiple Sclerosis","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    &lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    National MS Center Melsbroek&lt;br&#x2F;&gt;&lt;b&gt;Completed&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT04929145?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","published_date":"2021-06-17T16:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":97,"discovery_date":"2021-06-16T18:08:49","title":"Multiple Sclerosis and Voiding Symptoms: How to Assess?","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Multiple Sclerosis;   Lower Urinary Tract Symptoms;   Voiding Disorders&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Other: voiding phase evaluation&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Pierre and Marie Curie University&lt;br&#x2F;&gt;&lt;b&gt;Completed&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT04928716?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","published_date":"2021-06-16T16:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":96,"discovery_date":"2021-06-16T18:08:49","title":"Safety and Effectiveness of Cinnomer® (Glatiramer Acetate) in Multiple Sclerosis (MS) Treatment in Iran","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Relapsing Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Drug: Glatiramer Acetate&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Cinnagen&lt;br&#x2F;&gt;&lt;b&gt;Completed&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT04928313?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","published_date":"2021-06-16T16:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":95,"discovery_date":"2021-06-15T16:34:48","title":"Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis (MS)&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Drug: Fingolimod;   Drug: Ofatumumab;   Drug: Siponimod;   Other: Fingolimod placebo;   Other: Siponimod placebo;   Other: Ofatumumab placebo&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Novartis Pharmaceuticals&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT04926818?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","published_date":"2021-06-15T16:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":94,"discovery_date":"2021-06-14T17:57:48","title":"Study to Assess the Efficacy of Mayzent on Microglia in Secondary Progressive Multiple Sclerosis","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Secondary-progressive Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Drug: Mayzent;   Drug: Ocrevus&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Robert Zivadinov, MD, PhD&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT04925557?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","published_date":"2021-06-14T16:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":93,"discovery_date":"2021-06-14T17:57:48","title":"Observational Study in Patients With Relapsing-Remitting Multiple Sclerosis Switched to Bafiertam® From Dimethyl Fumarate","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Relapsing Remitting Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Drug: monomethyl fumarate&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Banner Life Sciences LLC&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT04925778?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","published_date":"2021-06-14T16:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":92,"discovery_date":"2021-06-08T15:45:00","title":"EEG and TMS-based Biomarkers of ALS, MS and FTD","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Amyotrophic Lateral Sclerosis;   Frontotemporal Dementia;   Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Procedure: 128 electrode electroencephalography (EEG);   Procedure: Transcranial magnetic stimulation (TMS)&lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    University of Dublin, Trinity College;   Motor Neurone Disease Association, UK;   Irish Research Council, IE;   Health Research Board, IE;   Research Motor Neurone, IE;   Thierry Latran Foundation, FR;   ALS Association, USA&lt;br&#x2F;&gt;&lt;b&gt;Recruiting&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT04918251?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","published_date":"2021-06-08T16:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":91,"discovery_date":"2021-06-08T15:45:00","title":"Motor Asymmetry in Progressive Multiple Sclerosis Patients","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Multiple Sclerosis, Primary Progressive;   Multiple Sclerosis, Secondary Progressive&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Radiation: Magnetic Resonance Imaging;   Diagnostic Test: Neurological examination;   Diagnostic Test: Multiple Sclerosis Functional Composite;   Diagnostic Test: Physiotherapist examination&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Rennes University Hospital&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT04918225?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","published_date":"2021-06-08T16:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":90,"discovery_date":"2021-06-03T15:01:28","title":"Exercise Booster Sessions in People With Multiple Sclerosis","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Combination Product: Systematic aerobic training;   Combination Product: Systematic resistance training;   Combination Product: Aerobic training booster sessions;   Combination Product: Resistance training booster sessions&lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    University of Aarhus;   Oxford Brookes University&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT04913012?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","published_date":"2021-06-03T16:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":89,"discovery_date":"2021-06-01T17:47:28","title":"A Comprehensive Assessment of Trunk, Scapula and Upper Limb in Neurological Patients. Reliability, Validity and Interrelatedness","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Multiple Sclerosis;   Stroke&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Other: Clinical Scapular protocol (ClinScaP);   Other: the prevalence of trunk, scapula and upper limb impairments.;   Other: the interaction between trunk, scapula and upper limb impairments.&lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    Hasselt University;   Revalidatie &amp; MS Centrum Overpelt;   Ziekenhuis Oost-Limburg;   National MS Center Melsbroek;   Jessa Hospital&lt;br&#x2F;&gt;&lt;b&gt;Recruiting&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT04908891?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","published_date":"2021-05-31T16:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":88,"discovery_date":"2021-06-01T17:47:28","title":"Evaluation of Safety, Tolerability and Preliminary Efficacy of EHP-101 in Relapsing Forms of Multiple Sclerosis","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Relapsing Forms of Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Drug: EHP-101 25 mg OD;   Drug: EHP-101 25 mg BID;   Drug: EHP-101 50 mg OD;   Drug: EHP-101 50 mg BID&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Emerald Health Pharmaceuticals&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT04909502?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","published_date":"2021-05-31T16:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":87,"discovery_date":"2021-06-01T17:47:28","title":"Creating Satisfying Engagement in Daily Life Through Coaching for People With Multiple Sclerosis","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Multiple Sclerosis;   Quality of Life&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Behavioral: Occupational Performance Coaching&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Queen&#39;s University&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT04908085?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","published_date":"2021-05-31T16:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":86,"discovery_date":"2021-05-28T12:44:08","title":"Evaluation of New MRI Sequences Including 3D-FGAPSIR for the Optimization of Inflammatory Spinal Cord Lesions Research","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Estimate the Number of Spinal Cord Lesions Detected With the 3D FGAPSIR Sequence That Were Not Detected With the 3D PSIR Sequence&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Device: MRI&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Fondation Ophtalmologique Adolphe de Rothschild&lt;br&#x2F;&gt;&lt;b&gt;Enrolling by invitation&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT04906928?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","published_date":"2021-05-28T16:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":85,"discovery_date":"2021-05-28T12:44:08","title":"Next-Gen MS: Feed-forward PRO Data for MS Research","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    &lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    EMD Serono Research &amp; Development Institute, Inc.&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT04907305?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","published_date":"2021-05-28T16:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":84,"discovery_date":"2021-05-28T12:44:08","title":"The Therapeutic Effects of Forced Aerobic Exercise in Multiple Sclerosis","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Behavioral: Forced Aerobic Exercise (FE);   Behavioral: Voluntary Aerobic Exercise (VE)&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    The Cleveland Clinic&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT04906057?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","published_date":"2021-05-28T16:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":83,"discovery_date":"2021-05-27T12:09:08","title":"Pilot Investigation to Evaluate FlowOx2.0™ for Experimental Treatment of Spasticity","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Multiple Sclerosis;   Spasticity, Muscle;   Pain&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Device: FlowOx™&lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    Otivio AS;   Haukeland University Hospital&lt;br&#x2F;&gt;&lt;b&gt;Recruiting&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT04904016?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","published_date":"2021-05-27T16:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":82,"discovery_date":"2021-05-26T15:30:08","title":"The Possible Neuroprotective Effect of Ocrelizumab Via VEGF Protein Expression in Relapsing Multiple Sclerosis Patients","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis Relapse&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    &lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    IRCCS National Neurological Institute &quot;C. Mondino&quot; Foundation&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT04902690?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","published_date":"2021-05-26T16:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":81,"discovery_date":"2021-05-20T11:40:26","title":"Swiss Study of the Impact of Mayzent on SPMS Patients in a Long-term Non-interventional Study","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Secondary Progressive Multiple Sclerosis With Inflammatory Disease Activity&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Other: Siponimod&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Novartis Pharmaceuticals&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT04895202?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","published_date":"2021-05-20T16:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":80,"discovery_date":"2021-05-19T11:05:28","title":"Adapting mHealth Technology to Improve Patient Activation","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Spinal Cord Injuries;   Stroke;   Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Behavioral: Fatigue self-management SMS intervention&lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    Washington University School of Medicine;   The Foundation for Barnes-Jewish Hospital&lt;br&#x2F;&gt;&lt;b&gt;Recruiting&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT04893590?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","published_date":"2021-05-19T16:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":79,"discovery_date":"2021-05-19T11:05:27","title":"Evaluation of Clinical, Morphologic and Biochemical Markers in Multiple Sclerosis","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Other: blood sample&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Medical University of Graz&lt;br&#x2F;&gt;&lt;b&gt;Recruiting&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT04892134?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","published_date":"2021-05-19T16:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":78,"discovery_date":"2021-05-18T10:30:26","title":"Investigation of the Effects of Technology Supported Different Physiotherapy Approaches on Patients With Multiple Sclerosis","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Other: Technology Supported Task-Oriented Circuit Training;   Other: Home-based Telerehabilitation&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Hacettepe University&lt;br&#x2F;&gt;&lt;b&gt;Active, not recruiting&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT04891341?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","published_date":"2021-05-18T16:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":77,"discovery_date":"2021-05-17T17:47:26","title":"Holter of Movement in Patients With Multiple Sclerosis in Controlled Environment.","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Device: Actimyo°;   Device: IMU&lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    Dr. Stéphanie Delstanche;   SYSNAV;   Centre Hospitalier Universitaire de Liège&lt;br&#x2F;&gt;&lt;b&gt;Active, not recruiting&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT04888689?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","published_date":"2021-05-17T16:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":76,"discovery_date":"2021-05-14T12:06:26","title":"The Effects of Respiratory-based Telerehabilitaion in Patients With MS","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Multiple Sclerosis;   Telerehabilitation;   Compliance, Patient&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Other: pulmonory based home exercises&lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    Dr. Anıl Tosun;   Trakya University&lt;br&#x2F;&gt;&lt;b&gt;Enrolling by invitation&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT04887051?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","published_date":"2021-05-14T16:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":75,"discovery_date":"2021-05-13T16:26:30","title":"Exploring the Immune Response to SARS-CoV-2 COVID-19 Vaccines in Patients With Relapsing Multiple Sclerosis (RMS) Treated With Ofatumumab","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Drug: Ofatumumab&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Novartis Pharmaceuticals&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT04869358?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","published_date":"2021-05-03T16:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":74,"discovery_date":"2021-05-13T10:18:31","title":"An Examination of Cognitive Fatigue Using Functional Neuroimaging","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis, Relapsing-Remitting&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Drug: Zeposia&lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    Kessler Foundation;   Celgene;   Hackensack Meridian Health;   St. Barnabas Medical Center&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT04885894?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","published_date":"2021-05-13T16:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":73,"discovery_date":"2021-05-12T10:42:31","title":"Holter of Movement in Patients With Multiple Sclerosis in Uncontrolled Environment.","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Device: Actimyo&lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    Dr. Stéphanie Delstanche;   SYSNAV;   Centre Hospitalier Universitaire de Liège&lt;br&#x2F;&gt;&lt;b&gt;Recruiting&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT04882891?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","published_date":"2021-05-12T16:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":72,"discovery_date":"2021-05-11T11:06:31","title":"Sport, Rehabilitation and Nutrition in Multiple Sclerosis: The LINUS Project","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Behavioral: B-HIPE (Brief High Impact Preparatory Experience)&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Fondazione Don Carlo Gnocchi Onlus&lt;br&#x2F;&gt;&lt;b&gt;Recruiting&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT04881422?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","published_date":"2021-05-11T16:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":71,"discovery_date":"2021-05-10T12:29:31","title":"Tenofovir Alafenamide for Treatment of Symptoms and Neuroprotection in Relapsing Remitting Multiple Sclerosis","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Multiple Sclerosis, Relapsing-Remitting;   Fatigue&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Drug: TENOFOVIR ALAFENAMIDE FUMARATE 25 Mg ORAL TABLET [VEMLIDY];   Drug: Placebo&lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    Harvard Medical School;   Gilead Sciences&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT04880577?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","published_date":"2021-05-10T16:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":70,"discovery_date":"2021-05-10T12:29:31","title":"Proof-of-concept Study for SAR441344 in Relapsing Multiple Sclerosis","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Drug: SAR441344 IV;   Drug: placebo IV;   Drug: SAR441344 SC;   Drug: placebo SC;   Drug: MRI contrast-enhancing preparations&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Sanofi&lt;br&#x2F;&gt;&lt;b&gt;Recruiting&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT04879628?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","published_date":"2021-05-10T16:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":69,"discovery_date":"2021-05-07T11:43:30","title":"Prevention of Clinical Multiple Sclerosis in Individuals With Radiologically Isolated Disease.","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Radiologically Isolated Syndrome;   Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Drug: Ocrelizumab;   Other: Placebo&lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    Yale University;   Genentech, Inc.&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT04877457?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","published_date":"2021-05-07T16:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":68,"discovery_date":"2021-05-07T11:43:30","title":"A Open-label Study to Assess Response to COVID-19 Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Relapsing Multiple Sclerosis (RMS)&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Drug: Ofatumumab;   Biological: mRNA COVID-19 vaccine;   Drug: interferon or glatiramer acetate&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Novartis Pharmaceuticals&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT04878211?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","published_date":"2021-05-07T16:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":67,"discovery_date":"2021-05-06T11:08:31","title":"Sonification Techniques for Gait Training","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Parkinson Disease;   Stroke;   Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Device: Gait rehabilitation with &quot;sonification&quot;;   Other: Standard gait rehabilitation (without sonification)&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Istituti Clinici Scientifici Maugeri SpA&lt;br&#x2F;&gt;&lt;b&gt;Recruiting&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT04876339?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","published_date":"2021-05-06T16:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":66,"discovery_date":"2021-05-06T11:08:31","title":"EMDR for Depressed People With Multiple Sclerosis","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Multiple Sclerosis;   Depression&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Behavioral: Eye Movement Desensitization and Reprocessing - EMDR&lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    Fondazione Don Carlo Gnocchi Onlus;   EMDR Europe;   Catholic University of the Sacred Heart&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT04875832?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","published_date":"2021-05-06T16:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":65,"discovery_date":"2021-05-05T10:42:09","title":"Sensor-based Assessment and Rehabilitation of Balance in Neurological Diseases","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Stroke;   Multiple Sclerosis;   Parkinson Disease&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Device: Experimental Group;   Other: Control Group&lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    IRCCS San Camillo, Venezia, Italy;   IRCCS San Raffaele;   Istituti Clinici Scientifici Maugeri SpA;   IRCCS National Neurological Institute &quot;C. Mondino&quot; Foundation;   I.R.C.C.S. Fondazione Santa Lucia&lt;br&#x2F;&gt;&lt;b&gt;Recruiting&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT04874051?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","published_date":"2021-05-05T16:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":64,"discovery_date":"2021-05-05T10:42:09","title":"Investigation of the Effect of Ocrelizumab on Peripheral Lymphocyte Immunophenotypes With Suppressive Capacity in MS","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Drug: Ocrelizumab&lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    Dr Recai Turkoglu;   Health Sciences University Istanbul Haydarpaşa Numune Training and Research Hospital&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT04874597?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","published_date":"2021-05-05T16:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":63,"discovery_date":"2021-05-05T10:42:09","title":"From Genetics to Transcriptomics to Unravel the Mechanisms Behind a Poor Outcome in Multiple Sclerosis","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Other: Biological sample collection&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Nantes University Hospital&lt;br&#x2F;&gt;&lt;b&gt;Recruiting&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT04873492?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","published_date":"2021-05-05T16:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":62,"discovery_date":"2021-05-03T11:30:09","title":"Exploring the Immune Response to SARS-CoV-2&#x2F;COVID-19 Vaccines in Patients With Relapsing Multiple Sclerosis (RMS) Treated With Ofatumumab","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Drug: Ofatumumab&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Novartis Pharmaceuticals&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT04869358?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","published_date":"2021-05-03T16:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":61,"discovery_date":"2021-04-30T10:48:20","title":"Validation of a Novel Instrument Task for Assessing Upper Limb","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Assessment of Arm and Hand Sensorimotor Functions in Multiple Sclerosis Subjects&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Other: Assessment of the upper limb (VPIT + PPIT)&lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    Swiss Federal Institute of Technology;   Kliniken Valens&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT04868370?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","published_date":"2021-04-30T16:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":60,"discovery_date":"2021-04-29T20:44:18","title":"Symptom Burden in Patients Treated With Ocrelizumab for Multiple Sclerosis","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Drug: Ocrelizumab&lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    NYU Langone Health;   Genentech, Inc.&lt;br&#x2F;&gt;&lt;b&gt;Recruiting&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT04855617?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","published_date":"2021-04-22T16:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":59,"discovery_date":"2021-04-28T12:01:02","title":"COVID-19 and Multiple Sclerosis Disease Modifying Therapies","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Covid19;   Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    &lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Nottingham University Hospitals NHS Trust&lt;br&#x2F;&gt;&lt;b&gt;Enrolling by invitation&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT04863586?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","published_date":"2021-04-28T16:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":58,"discovery_date":"2021-04-27T12:25:02","title":"Validation of the French Adaptation of the MSWDQ-23 Questionnaire","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Other: questionnaires&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Centre Hospitalier Universitaire de Nice&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT04860791?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","published_date":"2021-04-27T16:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":57,"discovery_date":"2021-04-27T12:25:02","title":"Assessment of sNfL Levels, Atrophy of the Macula GCC by OCT and Whole Brain Atrophy by MRI to Predict Evolution of Neurological Disability in MS Patients","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Diagnostic Test: Brain MRI;   Diagnostic Test: Spinal Cord MRI;   Diagnostic Test: Retinal imaging&lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    Centre Hospitalier Universitaire de Nīmes;   Institut de Recherches en Biothérapie&lt;br&#x2F;&gt;&lt;b&gt;Recruiting&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT04860947?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","published_date":"2021-04-27T16:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":56,"discovery_date":"2021-04-26T12:49:02","title":"MS Relapses During COVID-19 Pandemic","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Multiple Sclerosis;   Covid19;   Relapsing Remitting Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Other: No Intervention&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Nottingham University Hospitals NHS Trust&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT04858763?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","published_date":"2021-04-26T16:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":55,"discovery_date":"2021-04-23T20:54:01","title":"Effect of Variance on Error Correction During Coupling","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Multiple Sclerosis;   Progressive Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Other: synchronisation abilities&lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    Hasselt University;   National MS Center Melsbroek;   Noorderhart Revalidatie &amp; MS&lt;br&#x2F;&gt;&lt;b&gt;Recruiting&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT04856384?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","published_date":"2021-04-23T16:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":54,"discovery_date":"2021-04-23T20:54:01","title":"Running Title: Walking to Music and in Silence on a Treadmill","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Other: Walking with music with synchronisation;   Other: Walking with music without synchronisation;   Other: walking without music&lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    Hasselt University;   Noorderhart Revalidatie &amp; MS&lt;br&#x2F;&gt;&lt;b&gt;Recruiting&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT04856345?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","published_date":"2021-04-23T16:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":53,"discovery_date":"2021-04-23T20:54:01","title":"Deficient T Regulatory Cell (Treg) Function in Patients With Relapsing Remitting Multiple Sclerosis","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Relapse Remitting Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    &lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Thomas Jefferson University&lt;br&#x2F;&gt;&lt;b&gt;Recruiting&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT04857489?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","published_date":"2021-04-23T16:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":52,"discovery_date":"2021-04-22T20:19:01","title":"Investigating the Effects of Wearable Robotic Exoskeleton for Improving Mobility and Cognition in Persons With MS","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Multiple Sclerosis;   Gait Disorders, Neurologic;   Motility Disorder;   Cognitive Impairment&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Device: Robotic Exoskeleton Rehabilitation;   Other: Conventional Gait Therapy&lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    Kessler Foundation;   Kessler Institute for Rehabilitation&lt;br&#x2F;&gt;&lt;b&gt;Recruiting&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT04855825?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","published_date":"2021-04-22T16:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":51,"discovery_date":"2021-04-22T20:19:01","title":"Symptom Burden in Patients Treated With Ocrelizumab for Multiple Sclerosis. A Two-center, Prospective Observational Study","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Drug: Ocrelizumab&lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    NYU Langone Health;   Genentech, Inc.&lt;br&#x2F;&gt;&lt;b&gt;Recruiting&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT04855617?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","published_date":"2021-04-22T16:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":50,"discovery_date":"2021-04-21T10:57:40","title":"Investigation of the Effects of Selective Exercise Training in Multiple Sclerosis","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Multiple Sclerosis;   Exercise&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Other: exercise&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Sanko University&lt;br&#x2F;&gt;&lt;b&gt;Completed&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT04853654?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","published_date":"2021-04-21T16:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":49,"discovery_date":"2021-04-19T11:50:37","title":"GentleCath Air (Urinary Self-catheterization) - Pain in Female Patients With Neurological Vesico-sphincter Disorders","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Spinal Cord Injuries;   Multiple Sclerosis;   Parkinsonian Disorders;   Allodynia&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Device: GentleCath™ Air catheter&lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    ConvaTec Inc.;   ClinSearch&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT04847609?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","published_date":"2021-04-19T16:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":48,"discovery_date":"2021-04-19T11:50:37","title":"A Multicenter Study to Assess Response to COVID-19 Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Relapsing Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Other: Ofatumumab;   Other: Covid-19 vaccine&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Novartis Pharmaceuticals&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT04847596?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","published_date":"2021-04-19T16:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":47,"discovery_date":"2021-04-14T10:53:38","title":"Study of the Humoral Response to SARS-CoV-2 Variants and of the Cellular Response After Vaccination Against COVID-19 in Immunocompromised People","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Autoimmune or Autoinflammatory Diseases;   HIV;   Multiple Sclerosis;   Solid Tumors or Cancers;   Solid Organ Transplant&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Other: Blood samples for the study of the humoral response to SARS-CoV-2 variants and of the cellular response after vaccination against COVID-19&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Assistance Publique - Hôpitaux de Paris&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT04844489?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","published_date":"2021-04-14T16:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":46,"discovery_date":"2021-04-14T10:53:38","title":"Effects of Lutein Supplementation on Cognition and MPOD in Multiple Sclerosis Patients-","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Dietary Supplement: Lutein;   Dietary Supplement: Placebo&lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    University of Illinois at Urbana-Champaign;   Division of Nutritional Sciences, University of Illinois at Urbana-Champaign&lt;br&#x2F;&gt;&lt;b&gt;Recruiting&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT04843813?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","published_date":"2021-04-14T16:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":45,"discovery_date":"2021-04-14T10:53:38","title":"Covid19 Multiple Sclerosis Vaccine Biospecimen Study","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Drug: SARS-COV-2 mRNA Vaccine&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    NYU Langone Health&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT04843774?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","published_date":"2021-04-14T16:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":44,"discovery_date":"2021-04-09T13:11:11","title":"The Effect of Telerehabilitation Based Pilates Training in Multiple Sclerosis Patients","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Other: Telerehabilitation-based Pilates Exercise&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Gazi University&lt;br&#x2F;&gt;&lt;b&gt;Recruiting&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT04838886?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","published_date":"2021-04-09T16:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":43,"discovery_date":"2021-04-09T13:11:11","title":"TELEMS: Feasibility of Remote Patient Visits in MS","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Other: EDSS;   Other: Discussion of symptoms&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Medical University of Vienna&lt;br&#x2F;&gt;&lt;b&gt;Recruiting&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT04838990?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","published_date":"2021-04-09T16:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":42,"discovery_date":"2021-04-08T11:57:29","title":"Comparing the Antibody Response to COVID-19 Vaccination in Multiple Sclerosis Patients Treated With Ocrelizumab or Natalizumab","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Multiple Sclerosis;   Demyelinating Autoimmune Diseases, CNS;   Autoimmune Diseases of the Nervous System;   Nervous System Diseases;   Demyelinating Diseases;   Autoimmune Diseases;   Immune System Diseases;   Pathologic Processes&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Device: Elecsys semi-quantitative Anti-SARS-CoV-2 antibody test&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Dragonfly Research, LLC&lt;br&#x2F;&gt;&lt;b&gt;Recruiting&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT04837651?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","published_date":"2021-04-08T16:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":41,"discovery_date":"2021-04-08T11:57:29","title":"Retrospective Study on Registry Data to Evaluate the Impact of Ocrelizumab Used in Routine Care in Patients With RRMS","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    &lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    University Hospital, Strasbourg, France&lt;br&#x2F;&gt;&lt;b&gt;Recruiting&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT04838015?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","published_date":"2021-04-08T16:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":40,"discovery_date":"2021-04-08T11:57:29","title":"Effect of Disease Modifying Therapy on Antibody Response to COVID19 Vaccination in Multiple Sclerosis","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Multiple Sclerosis;   Covid19&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    &lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    St. Barnabas Medical Center&lt;br&#x2F;&gt;&lt;b&gt;Recruiting&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT04834401?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","published_date":"2021-04-07T16:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":39,"discovery_date":"2021-04-08T11:57:29","title":"Impact of Neuropsychological Disorders in Multiple Sclerosis","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Other: Three dimensional gait analysis with eyetracking&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Lille Catholic University&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT04837365?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","published_date":"2021-04-08T16:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":38,"discovery_date":"2021-04-08T11:57:29","title":"Therapeutic Adherence of Multiple Sclerosis Patients","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Other: Study of the role of sociocognitive factors&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Lille Catholic University&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT04837352?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","published_date":"2021-04-08T16:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":37,"discovery_date":"2021-04-06T11:14:24","title":"The Effects of Relaxation Techniques on Pain, Fatigue and Kinesiophobia in Multiple Sclerosis Patients: A Three Arms Randomized Trial","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Multiple Sclerosis, Relapsing-Remitting;   Pain, Chronic;   Fatigue Syndrome, Chronic;   Kinesiophobia&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Behavioral: PMR: Progressive Muscle Relaxation;   Behavioral: BRT:Benson Relaxation Technique&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Hacettepe University&lt;br&#x2F;&gt;&lt;b&gt;Completed&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT04833673?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","published_date":"2021-04-06T16:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":36,"discovery_date":"2021-04-05T11:38:24","title":"Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis Participants","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Relapsing Remitting Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Drug: Natalizumab&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Biogen&lt;br&#x2F;&gt;&lt;b&gt;Recruiting&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT04832399?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","published_date":"2021-04-05T16:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":35,"discovery_date":"2021-04-05T11:38:24","title":"Effects of a Multiple Sclerosis Relapse Therapy on Offspring Neurocognitive Development and Behaviour","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Other: Exposure to methylprednisolone during pregnancy&lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    Jena University Hospital;   Ruhr University of Bochum;   Interdisciplinary Center of Clinical Research of the Medical Faculty Jena;   Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany&lt;br&#x2F;&gt;&lt;b&gt;Recruiting&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT04832269?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","published_date":"2021-04-05T16:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":34,"discovery_date":"2021-03-30T11:05:24","title":"Imaging Evaluation of Central Nervous Autoimmune Diseases","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    MS (Multiple Sclerosis);   NMO Spectrum Disorder&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Diagnostic Test: MRI&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Qilu Hospital of Shandong University&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT04822623?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","published_date":"2021-03-30T16:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":33,"discovery_date":"2021-03-30T11:05:24","title":"Effects of Repeated Mesenchymal Stem Cells (MSC) in Patients With Progressive Multiple Sclerosis","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Biological: Mesenchymal Stem Cells (MSC)&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Hadassah Medical Organization&lt;br&#x2F;&gt;&lt;b&gt;Completed&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT04823000?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","published_date":"2021-03-30T16:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":32,"discovery_date":"2021-03-29T11:19:37","title":"Spinal Cord Lesion Detection in Multiple Sclerosis Using Novel MRI Sequences","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis (MS)&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Procedure: SC MRI;   Other: patient questionnaire&lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    University Hospital, Basel, Switzerland;   Freie Akademische Gesellschaft Basel&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT04819737?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","published_date":"2021-03-29T16:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":31,"discovery_date":"2021-03-29T11:19:36","title":"Study of the Mechanisms of Action of Cladribine in Multiple Sclerosis","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Other: biological collection&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    University Hospital, Rouen&lt;br&#x2F;&gt;&lt;b&gt;Recruiting&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT04821596?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","published_date":"2021-03-29T16:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":30,"discovery_date":"2021-03-26T13:30:35","title":"Botulinum Toxin A vs Anticholinergic Treatment of Neurogenic Overactive Bladder in Patients With Multiple Sclerosis","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Urinary Bladder, Neurogenic;   Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Drug: VESIcare 10Mg Tablet;   Drug: Botox 100 UNT Injection&lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    Brigitte Schürch;   Centre Hospitalier Universitaire Vaudois&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT04819360?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","published_date":"2021-03-26T16:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":29,"discovery_date":"2021-03-26T13:30:35","title":"The Effect of the Arabic Otago Exercise Program on Falls in People With Multiple Sclerosis","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Other: Otago Exercise Program&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    University of Jordan&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT04818008?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","published_date":"2021-03-26T16:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":28,"discovery_date":"2021-03-25T11:16:53","title":"Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Upper Limb Spasticity","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Spasticity;   Cerebrovascular Accident;   Multiple Sclerosis;   Traumatic Brain Injury;   Cervical Spinal Cord Injury;   Cerebral Palsy&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Drug: rimabotulinumtoxinB;   Drug: Placebo&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Supernus Pharmaceuticals, Inc.&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT04815967?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","published_date":"2021-03-25T16:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":27,"discovery_date":"2021-03-19T11:55:20","title":"Neuroplasticity of Cortical Areas Induced by Cognitive Training in Patients With Multiple Sclerosis MS-NEUROPLAST","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Multiple Sclerosis;   Cognitive Decline&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Other: Cognitive Training&lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    Aristotle University Of Thessaloniki;   King Fahad Medical City&lt;br&#x2F;&gt;&lt;b&gt;Active, not recruiting&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT04806568?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","published_date":"2021-03-19T16:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":26,"discovery_date":"2021-03-19T11:55:20","title":"Virtual Reality in Physical Therapy in Multiple Sclerosis","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Device: Neuroproprioceptive &quot;facilitation and inhibition&quot; in virtual reality;   Other: Neuroproprioceptive &quot;facilitation and inhibition&quot;&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Charles University, Czech Republic&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT04807738?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","published_date":"2021-03-19T16:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":25,"discovery_date":"2021-03-19T11:55:20","title":"Nature of the Link Between Executive Functions and Theory of Mind in Multiple Sclerosis","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Other: Theory of Mind&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Lille Catholic University&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT04806217?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","published_date":"2021-03-19T16:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":24,"discovery_date":"2021-03-18T11:23:53","title":"Emotions in Multiple Sclerosis","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Diagnostic Test: Carrying out a tests and questionnaires battery&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Lille Catholic University&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT04804787?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","published_date":"2021-03-18T16:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":23,"discovery_date":"2021-03-15T14:45:21","title":"Pathogenicity of B and CD4 T Cell Subsets in Multiple Sclerosis","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Multiple Sclerosis;   Clinically Isolated Syndrome&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Biological: blood sample;   Biological: cerebro-spinal fluid&lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    University Hospital, Bordeaux;   University of Bordeaux&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT04798651?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","published_date":"2021-03-15T16:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":22,"discovery_date":"2021-03-15T14:45:21","title":"Efficacy of COVID-19 Vaccination in Patients With Multiple Sclerosis Treated With Immune Modulating Medication","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Other: Analysis of cell-mediated and antibody-mediated immunity to SARS-CoV-2 virus&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Providence Health &amp; Services&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT04796584?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","published_date":"2021-03-15T16:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":21,"discovery_date":"2021-03-12T14:58:20","title":"Role of Individualized Versus Traditional Exercise in Combating Fatigue in Fatigued Multiple Sclerosis Patients","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Other: Adapted and individualized physical training program;   Other: traditional training program&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Centre Hospitalier Universitaire de Saint Etienne&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT04796272?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","published_date":"2021-03-12T17:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":20,"discovery_date":"2021-03-11T12:25:31","title":"Post-COntrast 3D SE T1 Versus Coronal SE T1-WI MRI in Detecting Optic Neuritis (COCON)","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Optic Neuritis;   Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Diagnostic Test: Magnetic Resonance Imaging&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Fondation Ophtalmologique Adolphe de Rothschild&lt;br&#x2F;&gt;&lt;b&gt;Completed&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT04793087?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","published_date":"2021-03-11T17:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":19,"discovery_date":"2021-03-11T12:25:31","title":"3D FLAIR Versus Coronal T2-WI MRI in Detecting Optic Neuritis (FLACON)","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Optic Neuritis;   Multiple Sclerosis;   Encephalopathy&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Diagnostic Test: Magnetic Resonance Imaging&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Fondation Ophtalmologique Adolphe de Rothschild&lt;br&#x2F;&gt;&lt;b&gt;Completed&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT04792866?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","published_date":"2021-03-11T17:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":18,"discovery_date":"2021-03-11T12:25:30","title":"Exploring the Immune Response to SARS-CoV-2 modRNA Vaccines in Patients With Secondary Progressive Multiple Sclerosis (AMA-VACC)","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Secondary Progressive Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Drug: BAF312;   Drug: Baseline disease modifying therapies (DMTs)&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Novartis Pharmaceuticals&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT04792567?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","published_date":"2021-03-11T17:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":17,"discovery_date":"2021-03-09T14:59:53","title":"Open Label Randomized Multicenter to Assess Efficacy &amp; Tolerability of Ofatumumab 20mg vs. First Line DMT in RMS","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Drug: Ofatumumab;   Drug: First line DMT&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Novartis Pharmaceuticals&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT04788615?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","published_date":"2021-03-09T17:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":16,"discovery_date":"2021-03-09T14:59:53","title":"T Cell Profiling in Patients With Multiple Sclerosis","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Other: Blood Sample&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Boston Children&#39;s Hospital&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT04789551?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","published_date":"2021-03-09T17:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":15,"discovery_date":"2021-03-08T13:43:03","title":"Behavioral Intervention for Physical Activity and Sexual Dysfunction in Multiple Sclerosis","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Multiple Sclerosis, Relapsing-Remitting;   Sexual Dysfunction&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Behavioral: Behavioural intervention for physical activity for multiple sclerosis (BIPAMS)&lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    University of Alabama at Birmingham;   National Multiple Sclerosis Society&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT04768777?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","published_date":"2021-02-24T17:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":14,"discovery_date":"2021-03-08T13:43:03","title":"miRNA Biomarkers in Multiple Sclerosis","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Multiple Sclerosis;   miRNA;   Epigenetic;   Biomarker&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Genetic: miRNA&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    University of Gaziantep&lt;br&#x2F;&gt;&lt;b&gt;Completed&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT04772495?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","published_date":"2021-02-26T17:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":13,"discovery_date":"2021-03-08T13:43:03","title":"Comparing the Safety and Benefit of Natalizumab (Tysabri®) At-home Infusion vs At-hospital Infusion in Multiple Sclerosis","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis (MS)&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Other: At-home natalizumab treated MS patient&lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    Nantes University Hospital;   Rennes University Hospital&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT04777539?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","published_date":"2021-03-02T17:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":12,"discovery_date":"2021-03-08T13:43:03","title":"ATOMIC (Active Teens Multiple Sclerosis) Physical Activity Research Program","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Pediatric Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Behavioral: Physical Activity (PA) Intervention;   Behavioral: Waitlist attention-control&lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    The Hospital for Sick Children;   Children&#39;s Hospital of Philadelphia;   University of Alabama at Birmingham;   Queen&#39;s University;   National Multiple Sclerosis Society&lt;br&#x2F;&gt;&lt;b&gt;Recruiting&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT04782466?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","published_date":"2021-03-04T17:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":11,"discovery_date":"2021-03-08T13:43:03","title":"Digital Gait Analysis in the Home Environment of Patients With Multiple Sclerosis","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    &lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    Medical Valley Digital Health Application Center GmbH;   Celgene Corporation;   NeuroSys GmbH;   Fraunhofer Institute for Integrated Circuits IIS;   Portabiles HealthCare Technologies GmbH;   University of Regensburg&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT04771858?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","published_date":"2021-02-25T17:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":10,"discovery_date":"2021-03-08T13:43:03","title":"Acceptability of Exoskeleton Assisted Walking for Persons With Mobility Issues Due to Multiple Sclerosis","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Multiple Sclerosis;   Pathologic Processes;   Sclerosis;   Autoimmune Diseases of the Nervous System;   Demyelinating Autoimmune Diseases, CNS;   Autoimmune Diseases&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Behavioral: Standard Exercise Training;   Device: Phoenix Exoskeleton suit&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Sheffield Teaching Hospitals NHS Foundation Trust&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT04786821?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","published_date":"2021-03-08T17:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":9,"discovery_date":"2021-03-08T13:43:03","title":"Addition of Belimumab to B-cell Depletion in Relapsing-remitting Multiple Sclerosis","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Drug: Belimumab;   Drug: Short-course Ocrelizumab;   Drug: Continued Ocrelizumab&lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    Johns Hopkins University;   GlaxoSmithKline&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT04767698?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","published_date":"2021-02-23T17:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":8,"discovery_date":"2021-03-08T13:43:03","title":"The Effect of Extra Virgin Olive Oil in People With Multiple Sclerosis","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Dietary Supplement: High Phenolic Extra Virgin Olive Oil&lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    University of Cyprus;   World Olive Center for Health;   Ellis-Farm, Eliama Daily Value&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT04787497?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","published_date":"2021-03-08T17:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":7,"discovery_date":"2021-03-08T12:17:02","title":"Extension to the MAGNIFY MS Trial on Mavenclad® (Magnify MS Extension)","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Drug: Mavenclad®&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT04783935?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","published_date":"2021-03-05T17:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":6,"discovery_date":"2021-03-08T12:17:02","title":"Cognition and HRQoL in Adults With Highly-active RMS in Year 3 and 4 After Initial Mavenclad® Dose (CLARIFY MS Extension)","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Drug: Mavenclad®&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany&lt;br&#x2F;&gt;&lt;b&gt;Recruiting&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT04776213?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","published_date":"2021-03-01T17:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":5,"discovery_date":"2021-03-02T14:12:09","title":"COVID-19: SARS Vaccination","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    SARS-CoV Infection;   COVID-19;   Allergic Reaction;   Mast Cell Disorder;   Non-atopic&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Biological: Moderna COVID-19 Vaccine;   Biological: Pfizer-BioNTech COVID-19 Vaccine;   Biological: Placebo&lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    National Institute of Allergy and Infectious Diseases (NIAID);   Immune Tolerance Network (ITN);   Rho Federal Systems Division, Inc.&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT04761822?term&#x3D;biontech&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","published_date":"2021-02-21T17:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":4,"discovery_date":"2021-03-01","title":"Antibody Response to COVID-19 Vaccines in Liver Disease Patients","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Chronic Liver Disease&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Biological: BNT162b2;   Biological: CoronaVac;   Biological: AZD1222&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Humanity &amp; Health Medical Group Limited&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT04775069?term&#x3D;biontech&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","published_date":"2021-03-01T17:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":3,"discovery_date":"2021-02-27","title":"Study to Evaluate the Safety, Tolerability, and Immunogenicity of SARS CoV-2 RNA Vaccine Candidate (BNT162b2) Against COVID-19 in Healthy Pregnant Women 18 Years of Age and Older","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    SARS-CoV-2 Infection;   COVID-19;   Maternal Immunization&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Biological: BNT162b2;   Other: Placebo&lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    BioNTech SE;   Pfizer&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT04754594?term&#x3D;biontech&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","published_date":"2021-02-15T17:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":2,"discovery_date":"2021-02-27","title":"National Cohort Study of Effectiveness and Safety of SARS-CoV-2&#x2F;COVID-19 Vaccines (ENFORCE)","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    SARS-CoV Infection&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Biological: COMIRNATY - BioNTech Manufacturing GmbH;   Biological: COVID-19 Vaccine Moderna dispersion for injection - MODERNA BIOTECH;   Biological: COVID-19 Vaccine AstraZeneca suspension for injection&lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    Jens D Lundgren, MD;   Ministry of the Interior and Health, Denmark&lt;br&#x2F;&gt;&lt;b&gt;Recruiting&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT04760132?term&#x3D;biontech&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","published_date":"2021-02-18T17:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1},{"trial_id":1,"discovery_date":"2021-02-27","title":"COVID-19: SARS Vaccination Reactions","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    SARS-CoV Infection;   COVID-19;   Allergic Reaction;   Mast Cell Disorder;   Non-atopic&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Biological: Moderna COVID-19 Vaccine;   Biological: Pfizer-BioNTech COVID-19 Vaccine;   Biological: Placebo&lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    National Institute of Allergy and Infectious Diseases (NIAID);   Immune Tolerance Network (ITN);   Rho Federal Systems Division, Inc.&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","link":"https://clinicaltrials.gov/ct2/show/NCT04761822?term&#x3D;biontech&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","published_date":"2021-02-21T17:00:00.000Z","source":"ClinicalTrials.gov","relevant":null,"table_constraints":null,"sent":1}]